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ABSTRACT 
Structure elucidation of a macromolecule can lead to the determination of 
its function.  In the case of proteins, knowledge of their three-dimensional 
structure can be utilised in the identification of active site(s) and 
consequently in rational drug design.  Commonly, X-ray crystallography is 
implemented on a high quality single crystal of the target macromolecule, 
in order to elucidate its structure.  Moreover, crystallised protein 
molecules may remain active which can then be used in controlled drug 
delivery.  Unfortunately, the successful crystallisation of a macromolecule 
can be seen as the most challenging aspect in this endeavour, given that 
predicting, screening and directing crystallisation remains an elusive goal. 
A possible solution to this problem is the use of heterogeneous nucleation, 
where a foreign surface is employed to lower the energy barrier for 
nucleation to occur.  Heteronucleation has been utilised in the 
crystallisation of small organic molecules, inorganic complexes, extended 
networks and proteins.  Polymeric surfaces, as heteronucleants, in protein 
crystallisation have been known to increase nucleation density rates and 
selectively crystallise particular forms of proteins.  Moreover, imprinted 
polymeric surfaces have been successfully used to selectively crystallise 
inorganic molecules as well as a small range of well studied proteins. 
This thesis presents the effects of polymers on the crystallisation of two 
proteins, that of mutant human thioredoxin and wild-type hen egg-white 
lysozyme (HEWL).  Polymers were used in solution, as physically adsorbed 
films as well as plasma polymers.  Shape and size of the protein crystals 
was altered, while polymorphism was also achieved, in the presence of 
polymers with various functionalities.  This work is a step towards the use 
of polymers as heteronucleants in directing protein crystallisation.   
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CHAPTER 1 
1. Introduction 
1.1. Prologue 
This chapter introduces the aim of this work and defines its objectives.  To 
set the scene of the research this chapter will cover crystallisation, its 
basic principles, various techniques of crystallisation, challenges that have 
risen thus far, as well as research conducted in predicting and controlling 
crystallisation.  It will explain why there is a need to crystallise proteins, 
and focus on polymers and their uses in protein crystallisation.  
Furthermore, the premise of the research will be presented and the 
proteins utilised in the thesis will be introduced. 
 
1.2. Why Crystallise Proteins? 
The three-dimensional structure of a biological macromolecule (nucleic 
acid, protein, virus) can play a vital role towards understanding the 
function of said macromolecule.   
In the case of proteins, these polypeptides are formed out of 20 naturally 
occurring amino acid residues which are covalently linked via peptide 
bonds to form the primary structure of each protein.  The chemical 
properties of the amino acids (hydrophilicity, hydrophobicity, charged, 
uncharged) that comprise a protein determine how these residues interact 
with one another within the protein.  Protein structure is primarily driven 
by the non-covalent interactions of the protein residues. Hydrogen 
bonding between the residues of the protein stabilise the formation of sub-
VWUXFWXUHVVXFKDVDOSKDĮ-KHOLFHVDQGEHWDǃ-) sheets, which give rise 
to the secondary structure of a protein.   
CHAPTER 1 Introduction 
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The tertiary structure of a protein refers to its final three-dimensional 
structure, where the secondary structures are folded further, driven by 
several non-covalent interactions, such as hydrogen bonding, hydrophobic 
interactions, electrostatic interactions and Van der Walls forces.  The 
domains formed by these interactions can be further stabilised by salt 
bridges and/or covalent disulphide bonds.  Moreover, certain proteins, 
such as haemoglobin, have a quaternary structure which is formed when 
two or more polypeptides interact to form the final protein structure. The 
polypeptides that comprise quaternary structured proteins can be identical 
or different subunits which are then stabilised by the same non-covalent 
interactions as those giving rise to the tertiary protein structure, as well as 
disulphide bridges.  The complexity of the three-dimensional structure of a 
protein is illustrated in Figure 1.1. 
The folding of amino acid residue chains and the formation of the three-
dimensional structure of a protein needs to be elucidated in order to 
identify active site(s), possible areas of interactions with other 
(macro)molecules, or similarities in structure with other known proteins, 
which can lead to function elucidation.  While there are crystal structure 
prediction software, such as I-TASSER, that can be used to predict the 
possible structure and function of a protein based on its primary structure, 
the software results are not 100% reliable.  
Nuclear magnetic resonance (NMR) spectroscopy can be employed to 
determine the three-dimensional structures of proteins.  Solution NMR is 
usually limited in the structural elucidation of small proteins (35 kDa), 
due to the complexity of the NMR spectra produced by larger proteins.  
However, recent advances have led to the structural elucidation of large 
proteins, such as the 900 kDa bacterial chaperone complex GroEL-GroES 
(1).  An advantage of solution NMR is that it provides data consistent with 
CHAPTER 1 Introduction 
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a number of possible structures for the same protein, which in turn 
provide a more dynamic view of the protein structure. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Schematic representation illustrating the structural complexity of 
proteins, using human haemoglobin as an example.  Haemoglobin is a tetrameric 
globular protein comprised of WZR Į DQG WZR ǃ VXEXQLWV  The (a) primary structure of 
haemoglobin consists of the 141 and 146 amino acid sequence of the Į DQG ǃ VXEXQLWs 
respectively.  The (b) secondary, (c) tertiary and (d) quaternary structure of haemoglobin is 
also depicted. The quaternary structure of the protein was determined by B. Shaanan using 
X-ray crystallography (2).  
The most common method for protein structure elucidation is X-ray 
crystallography (3) and accounts for 87% of the structures deposited in 
the Protein Data Bank (PDB) (4).  The target protein must undergo 
crystallisation in order to afford a high quality large single crystal.  X-ray 
crystallography is then employed and a diffraction pattern of the crystal is 
obtained, which is used to elucidate the protein structure.  In comparison 
to solution NMR, a single protein structure is obtained, which gives a more 
(a)
(b) (c)
(d)
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static view of the protein structure.  However, X-ray crystallography is not 
limited by the size of the protein.  Synchrotron X-ray sources, like the 
Diamond Light Source in Oxfordshire, can analyse small crystals ǋP
in all dimensions), while conventional X-ray sources can analyse larger 
crystals (50±250 ǋPLQDOOGLPHQVLRQV(5).  
Once the native structure (i.e. natural, unaltered structure) of a protein is 
known, rational drug design can also be employed.  For example, in 
diseases such as cancer, certain biological pathways can be activated by 
particular proteins.  Knowledge of the three-dimensional structure of those 
proteins can be used in rational drug design, resulting in the synthesis of 
drug molecules that are designed to fit and bind into the active site(s) of 
the target proteins, thus blocking protein function.  A successful example 
of structure-based rational drug design is imatinib, marketed as Glivec 
(Europe) or Gleevec (USA).  It was designed specifically as an inhibitor to 
the bcr-abl fusion protein, which is a tyrosine kinase, caused by a 
chromosomal translocation (the Philadelphia chromosome) found in 
chronic myelogenous leukaemia (CML).  As imatinib targets this specific 
tyrosine kinase fusion protein, it is able to target selectively the cancer 
cells of the patient (6). 
Aside from structure/function elucidation and rational drug design, protein 
crystallisation is also important in controlled drug delivery.  Drug levels in 
a human organism cannot be sustained over a prolonged period of time, 
GXHWRWKHERG\¶VPHWDEROLVP.  In order to confirm that crystallised protein 
macromolecules have remained in active form within the crystal lattice, 
activity assays can be utilised.  The non-covalent bonds that connect the 
crystallised protein molecules can then be broken resulting in individual 
active protein macromolecules.  Thus, drugs that are proteins, such as 
insulin, in the form of crystals show promise in controlled delivery, when 
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encapsulated within biodegradable polymer shells, which serve to protect 
the protein and allow for controlled drug release (7).  Uniform sized 
crystals are required for the dosing to be reproducible, when using 
crystallised proteins as drugs.  
Therefore, protein crystallisation can be utilised for structure/function 
elucidation, rational drug design as well as controlled drug delivery.  Since 
the first protein crystallisation, that of earthworm haemoglobin in 1840 by 
Hünefeld, to today, protein crystallisation is proving a challenging area of 
research.  While there are attempts at using bioinformatics in order to 
predict whether a protein can crystallise (8), the successful prediction and 
control of protein crystallisation remains elusive mainly due to the fact 
that every protein has a unique three-dimensional structure with different 
surface characteristics.  Moreover, difficulties in extracting and purifying 
the target protein (prior to crystallisation), problems with protein solubility 
or even the limited amount of protein purified (once extracted from 
samples), are frequently encountered.  
There are commercial screening kits (9) available that offer a variety of 
crystallisation conditions, by varying in salts, buffers and precipitants.  Use 
of such kits can lead to the identification of suitable salt/buffer/precipitant 
conditions for the successful crystallisation of a particular protein.  Subtle 
changes in the crystallisation conditions may afford different crystal forms 
of the target macromolecule. 
 
1.3. Basic Principles of Crystallisation 
The word µcrystal¶ GHULYHG IURP WKH *UHHN ZRUG µǉǏǘıĲĮǊǊǎǐ¶ PHDQLQJ
clear ice, is used to describe a homogeneous solid that is formed by an 
orderly three-dimensional array of atoms, ions, molecules, or molecular 
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assemblies held together by non-covalent interactions.  Single crystals 
appear transparent and can have distinct geometrical crystal classes 
(triclinic, monoclinic, orthorhombic, tetragonal, rhombohedral, hexagonal, 
cubic), with regular faces and well-defined edges (Table 1.1). 
Crystal System 
Crystals get grouped 
in one of the seven 
crystal systems 
according to the 
three types of 
symmetry: plane, 
axis and centre of 
symmetry 
Plane of Symmetry 
Represents an 
imaginary plane 
through the centre of 
the crystal dividing 
the crystal into two 
halves, both being 
mirror images of 
each other (10) 
Axis of Symmetry 
Represents an 
imaginary line 
through the centre 
of a crystal so that 
the rotation of the 
crystal about this 
line results in the 
arrangement of 
faces and angles 
being identical with 
that of the starting 
position (10) 
Centre of Symmetry 
The point at which all 
the axes meet  and 
through which the 
planes of symmetry 
pass (10) 
Triclinic 0 0 axes 1 or 0 
Monoclinic 1 1 two-fold axis 1 
Orthorhombic 3 3 two-fold axes 
mutually 
perpendicular 
1 
Tetragonal 5 1 four-fold axis 1 
Rhombohedral 3 1 three-fold axis 1 
Hexagonal 7 1 six-fold axis 1 
Cubic 9 minimum of 4 three-
fold axes 
1 
 
Table 1.1. Table showing the seven crystal systems and the three types of 
symmetry used to categorise crystal structures: plane, axis and centre of symmetry 
(11).  The crystal systems are presented in order of least to most symmetric.  
Crystallisation is the process by which crystals are formed in three stages: 
nucleation, growth of crystal(s) and termination of crystal growth.  
Crystals can be formed from solutions, melts and gases.  Crystallisation is 
a reversible equilibrium phenomenon, driven by the minimisation of the 
system¶s free energy (12).  To crystallise solute molecules from a solution, 
it is necessary for the molecules to be at a supersaturated state.  In a 
supersaturated solution there is such an increased amount of solute 
molecules that they are not fully solvated.  A supersaturated solution is a 
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chemical system that is not at equilibrium. The system is 
thermodynamically driven to a new equilibrium state with a new free 
energy minimum, where solute molecules are driven out of solution and 
into the solid state.  Aggregation of solute molecules, and formation of 
non-covalent bonds between them, minimises the free energy of the 
system.  Thus, due to kinetics, nucleation is most practically achieved at 
higher levels of supersaturation than those used for crystal growth.   
Nuclei formation is affected by diffusion and convection.  Convection 
currents are formed as regions near the growing crystal have a lower 
crystallising molecule concentration than the rest of the solution, resulting 
in the formation of density gradients (13).  Crystallising solute molecules, 
at a supersaturated state, have a higher energy than solutes in a 
crystalline state.  In order to reach the crystalline state a critical nucleus 
must be formed, which has a higher energy than the free solute 
molecules.  This is the energy barrier that must be overcome prior to 
crystal formation.  The speed at which the critical nuclei appear, 
determines the rate at which nucleation occurs (14). 
Nuclei are unstable and can spontaneously dissolve unless they reach 
µFULWLFDOVL]H¶ZKLFKLVdetermined by the ratio between surface area of the 
nucleus and its volume (15).  Once stable nuclei are formed they can grow 
further to form crystals.  Studies have shown that the rate of crystal 
growth is constant in a supersaturated solution, until termination of crystal 
growth occurs, provided that all other variables, such as temperature, 
remain constant (16). 
CHAPTER 1 Introduction 
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Figure 1.2. Schematic drawing of a protein crystallisation phase diagram based on 
two of the most commonly varied parameters, protein and precipitant 
concentrations.  The four major crystallisation methods are highlighted showing that in 
order to produce crystals, all the systems need to reach the same destination, namely the 
nucleation zone, after which they make their way through the metastable zone and 
eventually arrive at the solubility curve.  Each method achieves this journey via a different 
route.  The black dots ( represent the starting conditions.  In the case of dialysis and free-
interface diffusion two alternative starting points are shown since the undersaturated protein 
solution can contain solely protein or alternatively, protein with a low concentration of the 
precipitating agents (17). 
Figure 1.2 is a typical crystallisation phase diagram.  The undersaturation 
zone is where most vapour and liquid diffusion crystallisation experiments 
start. The types of crystallisation experiments are explained further in 
section 1.4. There are four zones of supersaturation; the precipitation 
zone is the highest supersaturation zone where proteins have random 
intermolecular interactions at a faster rate and as a result amorphous 
precipitate forms. The nucleation (labile) zone is of moderate 
supersaturation and under those conditions  ordered, periodical 
intermolecular interactions take place at a slower rate and may result in 
the formation of crystal nuclei (18).  The metastable zone is a lower 
supersaturation phase where the conditions observed are ideal for the 
growth of well-ordered crystals.  At the metastable zone no crystal 
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nucleation may take place (19).  The end point of a crystallisation 
experiment is the solubility curve, which is a dynamic equilibrium where 
the crystal is stable. 
Crystal growth is terminated either due to concentration decrease of the 
crystallising solute (towards reaching equilibrium), or due to the fact that 
the crystal has reached a certain size and cannot grow further.  The time 
required for large single crystals to form can vary from a few days to 
several months (20). 
Incorporation of impurities or damaged crystallising solute molecules, in 
the growing face of a crystal, leads to interruption of the growing crystal 
ODWWLFH7KLVLVFDOOHGµSRLVRQLQJ¶RIWKHFU\VWDODQGWKHFDXVHGGLVUXSWLRQ
in the internal order of the crystal, over many atomic dimensions, can lead 
to the loss of crystalline properties, such as shape, regular faces and well-
defined edges (18). 
Inorganic compounds, such as minerals, as well as organic compounds, 
such as sugars and proteins, can be crystallised under certain conditions.  
Subtle changes in the crystallisation conditions can alter the relative 
arrangement of the crystallising molecules within the crystal, resulting in 
crystals that belong to different crystal systems.  The various crystal forms 
arising from the same crystallising molecule are called polymorphs, of said 
compound.  Polymorphs have different physical properties, such as crystal 
habit (i.e. crystal size and shape), melting point and dissolution rate.  
Thus, under patent law, a new crystal form of a compound can be 
considered as an innovation.  An example of polymorphism can be seen in 
acetaminophen, which has three polymorphs: monoclinic (form I), 
orthorhombic (form II) and form III which is a metastable bilayer 
structure (21, 22).  In the case of proteins, the term forms, and not 
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polymorphs, is used since each protein crystal form has a unique 
composition arising from variable water content and buffer components.  
While supersaturation of the system drives both nucleation and crystal 
growth, the rate of nucleation differs from the crystal growth rate.  Both 
rates can affect the habit of the crystal (i.e. shape and size) as well as 
crystal quality.  Multiple crystal nuclei and a fast crystal growth rate can 
result in the formation of numerous microcrystals.  Few crystal nuclei and 
a slow crystal growth rate usually results in large, single crystals, which 
are more desirable for single crystal X-ray crystallography analysis.  
Moreover, altering the rates of nucleation and crystal growth may result in 
the formation of a different crystal polymorph/form (23). 
Other factors which affect protein crystallisation include purity of the 
protein sample, temperature, pH and precipitant type.  A common 
precipitant is salt (NaCl), which can compete with protein molecules for 
solvent molecules, rHVXOWLQJ LQD µVDOWLQJRXW¶HIIHFW, as protein molecules 
are forced to self-associate in order to fulfil their electrostatic 
requirements.  Crystallisation pH is chosen according to the optimum pH 
range of the protein (so as not to denature it) and taking into 
consideration the isoelectric point of the protein (pI).   
Temperature is an important factor in protein crystallisation and should be 
maintained within Û&in order to achieve replicable and reliable results; 
unless temperature variation is desired in the experiment.  As the 
solubility of proteins is temperature dependant, and could decrease or 
increase depending on the target protein, crystallisation usually takes 
place between 4ÛC to 19ÛC DQG FDQ HYHQ UHDFK Û& ZLWK WKH XVH RI
incubators, which are set at a constant temperature (24). Temperature 
affects the kinetics of crystallisation.  For example, if low temperatures 
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decrease the solubility of a specific protein, they can lead to 
supersaturation but also decrease diffusion, due to low kinetics, resulting 
in slow crystal growth.  E[SHULPHQWV FRQGXFWHGRQSRUFLQHSDQFUHDWLFĮ-
amylase demonstrated that the growth rate of AI and BII crystal forms 
increased dramatically when WHPSHUDWXUHZDVLQFUHDVHGDERYHÛ& (25).   
As for protein sample purity, it is paramount in order to grow a high 
quality single crystal without impurities µpoisoning¶ the crystal during its 
formation.  Ligands, such as drugs, can sometimes be added to a protein 
sample, in order to stabilise the conformation of the protein and allow for 
crystallisation to take place. 
 
1.4. Crystallisation Techniques 
There are various crystallisation techniques, the three most popular, in 
descending order of popularity, are vapour diffusion, batch and dialysis 
(26).  Each of these techniques should achieve supersaturation by the 
slow increase in concentration of some precipitant, such as salt or 
polyethylene glycol (PEG) (Figure 1.2).  During use of these techniques 
other factors can also be altered, such as pH and temperature. 
 
1.4.1. Vapour Diffusion Crystallisation 
The technique used during this research is the vapour diffusion method, 
which is the most popular, as it can be used to screen a broad range of 
crystallisation conditions, using small amounts of materials, but can also 
be scaled up in order to obtain large crystals for X-ray diffraction analysis.  
Vapour diffusion can be separated into three procedures; the sitting drop, 
the hanging drop and the sandwich drop vapour diffusion techniques 
(Figure 1.3).  A drop of 1:1 protein:precipitant solutions is usually used 
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and it is either supported by a surface (sitting drop), or is suspended from 
a surface (hanging drop).  Furthermore, the drop can be in contact with 
both an upper and a lower surface (sandwich drop). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Schematic depicting three of the most common crystallisation 
techniques: (a) vapour-diffusion, (b) microbatch and (c) dialysis (17).  
The entire system is sealed using vacuum grease and a cover slip, or using 
transparent crystallisation sealing tape (with a chemically inert adhesive).  
This prevents solvent being lost to the external environment. The 
difference in precipitant concentration between the drop and the reservoir 
solution causes water to diffuse away from the drop.  This continues until 
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Macromolecule         Precipitant ions or molecules (ppt)
(a)
Sample well Reservoir well Sealing tape
(b)
Vacuum grease Reservoir well
[ppt]drop= [ppt]reservoir /2ĺ [ppt]drop=[ppt]reservoir
H2O
H2O
the concentration of the precipitant in the drop is the same as that of the 
reservoir well solution (Figure 1.4).  Thus equilibration takes place through 
the vapour phase. 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Schematic depicting (a) sitting and (b) hanging drop vapour diffusion 
crystallisation taking place in a single well environment.  The reservoir has usually 
twice the concentration of precipitant than the sitting/hanging drop.  Water loss from the 
drop via vapour diffusion, reduces the volume of the drop and as equilibration takes place, 
WKHFRQFHQWUDWLRQRIWKHGURS¶VFRPSRQHQWVLQFrease significantly.  
Water loss from the drop to the reservoir solution causes reduction in the 
volume of the drop, which in turn increases the concentrations of all the 
solutes within it.  Thus, precipitant and protein concentrations increase.  
Absorption of water by the air sealed in each microenvironment, at the 
beginning of the experiment, further increases the supersaturation level 
within the drop so that ideal nucleation levels of supersaturation are 
achieved (Figure 1.2). 
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The equilibration process can be slowed by reducing the surface area over 
which diffusion occurs, such as when the sandwich drop vapour diffusion 
technique is used, or by increasing the distance between the drop and the 
reservoir.  For the hanging drop technique glass cover slips are used to 
suspend the drop.  The cover slips are usually siliconised to obtain a 
hydrophobic surface, thus to prevent wetting and the drop from spreading 
(24).  The same vapour diffusion principle applies to both sandwich and 
hanging drop techniques. 
 
1.4.2.  Batch Crystallisation 
Batch crystallisation is the oldest and simplest crystallisation technique.  
In the batch method the concentrated protein solution is mixed with 
concentrated precipitant in a well, and the contents are covered with 
paraffin oil to prevent evaporation (Figure 1.3).  This produces a final 
supersaturated solution immediately upon mixing which may lead to 
crystallisation (Figure 1.2).  The volume of the drop and the precipitant 
concentration remain the same.  Formation of protein crystals or protein 
precipitant can alter the protein concentration.  Rapid equilibration during 
this technique can affect the rate of crystal growth and the quality of the 
crystals obtained.   
Large amounts of solution WKDW W\SLFDOO\ UDQJH IURP  ǋO WR VHYHUDO
millilitres are used in batch crystallisation, which can lead to larger crystals 
forming. In contrast, microbatch techniques require the use of smaller 
volumes (nanolitre to microlitre volumes) and are preferred for screening 
trials (17).  Microbatch under oil, which was developed in the 1990s, is 
compatible with most precipitants, buffers and additives.  However, this 
technique should not be used when small volatile organic molecules such 
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as dioxane, phenol and thymol are present, due to the fact that these 
chemicals are soluble in oil (27).  
 
1.4.3. Dialysis Crystallisation 
In the dialysis method the macromolecule solution is separated from the 
precipitant/crystallisation mixture by a membrane with a molecular weight 
limited permeability.  The small precipitant molecules (ions, additives, 
buffers, etc.) can freely diffuse through the semi-permeable membrane in 
order for equilibration to take place, while the target 
macromolecules/proteins are unable to diffuse through the membrane 
(Figure 1.3) (18).  In this technique the protein concentration is held 
constant while the precipitant concentration increases (Figure 1.2).  
Dialysis is used as a crystallisation method mainly for optimisation, once 
the conditions for crystallisation have been primarily identified by a more 
efficient method, such as vapour diffusion or microbatch crystallisation 
(27).  
 
1.5. Nucleation 
During the nucleation stage the formation of the first ordered aggregates 
signals the start of crystallisation, which is then followed by crystal 
growth.  As mentioned in section 1.3, it is necessary to overcome the 
energy barrier that the crystalline state presents in comparison to the free 
solute molecules, thus it requires a higher supersaturation state than the 
one needed for crystal growth (24).   Nucleation, and its mechanism, has 
been studied in detail as it is a key step towards crystal formation (28-30).  
Once critical nuclei have been formed and nucleation has been successful, 
crystal growth follows spontaneously (14, 24, 31).  However, if nucleation 
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conditions persist, i.e. high supersaturation levels, then either multiple 
nuclei can result in amorphous precipitate or crystals that are too small in 
size to be used for analysis, such as X-ray crystallography, may form as a 
result (32).  Nucleation can be affected by a number of factors, aside from 
supersaturation, such as well shape, drop volume and the geometry of the 
reservoir in a crystallisation experiment (24), given that changing the 
surface and volume energies, according to the Gibbs-Thomson equation 
also increases the nucleation frequency (29). 
 
1.5.1. Homogeneous Nucleation 
The crystallisation of a target macromolecule into a large, high quality, 
VLQJOH FU\VWDO FDQ EH VHHQ DV WKH µUDWH OLPLWLQJ VWHS¶ LQ WKH VWUXFWXUH
elucidation process.  Homogeneous nucleation occurs when nuclei 
spontaneously grow and form crystals in the bulk of the solution.  
Homonucleation crystallisation is less frequently employed in research due 
to the critical energy barrier that must be overcome for ordered nuclei to 
form.   
 
1.5.2. Heterogeneous Nucleation 
Heterogeneous nucleation takes place when the surface of a foreign 
substance lowers the energy barrier for the aggregation of molecules to 
occur, inducing nucleation, E\ DFWLQJ DV DQ µDQFKRU¶ IRU WKH FU\VWDOOLVLQJ
molecules (Figure 1.5).  Heterogeneous nucleation is perceived as a key 
step towards predicting, screening and directing protein crystallisation, 
given that it facilitates crystal formation at lower supersaturation values 
and increases nucleation frequency (33). 
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Figure 1.5. Schematic representation of heterogeneous nucleation during protein 
crystallisation.  Nucleation occurs at surfaces preferentially.  In general, biological 
macromolecules tend to adsorb to surfaces that offer attractive chemical, electrostatic or 
structural features that favour interaction, i.e. when there is functionality complementary 
between the heterogeneous nucleant surface and the crystallising molecules.  
Examples of heterogeneous nucleation are seen when crystals grow 
attached to glass or plastic surfaces, or found associated with some type 
of debris, such as hair or fibres (34-36)  (Figure 1.6).  Time lapse video 
microscopy has been used to study the importance of surfaces in the 
earliest stages of crystal formation (37).   
 
 
 
 
Figure 1.6. Photomicrograph showing hen egg-white lysozyme (HEWL) crystals 
nucleating on a fibre.  
Nucleation occurs at surfaces preferentially.  In general, biological 
macromolecules tend to adsorb to surfaces that offer attractive chemical, 
electrostatic or structural features that favour interaction, i.e. when there 
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is complementarity between the heterogeneous nucleant surface and the 
crystallising molecules (14).  Molecules adsorbed to surfaces are spatially 
constrained, so they translate (move) in to two-dimensions rather than 
three, or are partially immobilised.  This assists in nuclei formation, since 
the crystallising molecules are immobilised and can become part of an 
ordered array (14).  
As such, a heterogeneous nucleant (also called substrate or 
heteronucleant) can be seen as a crystallisation catalyst; which helps 
lower the energy barrier for aggregation of molecules and induce 
nucleation, by concentrating or immobilising the crystallising molecules in 
such a way that they tend to nucleate and crystallise (14). 
Homogeneous and heterogeneous nucleations proceed by chance 
attachment and dissociation of particles.  However, in heterogeneous 
nucleation the induction period of forming critical nuclei is reduced (38), 
the supersaturation levels for crystallisation can be lowered (39, 40), while 
the observed nucleation density rates tend to increase (40), when 
compared to homogeneous nucleation.  
Heterogeneous nucleation can occur when materials of various natures are 
introduced in crystallisation experiments either as surfaces of support to 
the drop containing the crystallisation target (macro)molecules or added 
directly into the crystallising mixture (23, 33, 40-43). 
Heterogeneous nucleation, where the surfaces were made out of cross-
linked polymers, has been used to selectively crystallise certain crystal 
forms of organic molecules (44-48), inorganic complexes (49) and 
extended networks (50).  Heterogeneous nucleation of proteins has also 
been studied, using the following heterogeneous nucleants: minerals (51, 
52), human hair (53), horse hair (54), polymers (23, 39, 40, 55, 56), 
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hydrophobic self-assembled monolayers (5), porous glass and silicon (43, 
57, 58), silicon-based devices (59), and chemically treated glass surfaces 
(60, 61).  
In parallel, research lead by E. Drioli over the last decade (62) has 
resulted in the development of a membrane-based technology, named 
³PHPEUDQH FU\VWDOOLVDWLRQ´ 3orous hydrophobic polypropylene 
membranes (Accurel® PP V8/2 HF) (63) were successfully utilised in 
crystallisation experiments to adjust the solution composition, from an 
undersaturated state to a supersaturated state and act as heterogeneous 
nucleants (64).  These membranes used in vapour diffusion experiments 
(64, 65) have resulted in the crystallisation of inorganic (66), organic (67), 
(bio)macromolecular (68, 69) compounds, as well as active 
pharmaceutical ingredients, such as carbamazepine (anticonvulsant) (70).   
 
1.6. Polymer Mediated Crystallisation 
As mentioned above, various materials have been utilised as 
heteronucleants in recent research; however, they have not been proven 
as successful µXQLYHUVDO¶KHWHURQXFOHDQWV that can be potentially employed 
in the crystallisation of most biological molecules. An ideal 
heteronucleant(s) would be able to promote crystallisation in most 
biological systems. The heteronucleant(s) should be able to be 
incorporated in the existing crystallisation formats available and have a 
diverse functionality, which is vital considering the unique three-
dimensional structure and nature of biological macromolecules, as 
demonstrated by proteins.   
A considerably successful candidate to the quest of a universal 
heteronucleant for small molecule single-crystal production has been 
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observed in the use of polymer-induced heteronucleation (71).  This is due 
to the functional diversity observed in polymer libraries, which have been 
able to crystallise a broad range of pharmaceuticals (45, 72, 73) and other 
compound classes (50) from various aqueous and organic solutions. 
Therefore, the range of polymer libraries available could also be used for 
heterogeneous nucleation in protein crystallisation.  For example, Liberski 
et al. (47) used commercially available polymers as well as cross-linked 
and linear copolymers to create polymer microarrays (74), in order to 
screen well studied small molecules, such as carbamazepine and 
sulfamethoxazole, for polymorphism.  This high throughput technique 
produced a large amount of data (3 molecules, each crystallised on 128 
different polymers), and the crystals were characterised using optical and 
Raman spectroscopy.  Unfortunately, the absence of polymer surface 
characterisation resulted in a lack of concluding remarks between crystal 
polymorphs and the surfaces which induced them.  
Foroughi et al. (75) further demonstrated that polymer-induced 
heteronucleation can be applied to protein crystallisation successfully, by 
optimising the heteronucleant composition and crystallisation formats in 
order to crystallise a wide range of protein targets, also resulting in 
increased crystal size as well as the discovery of two new forms of 
concanavalin A and the structural elucidation of one of these forms.  
Using parallel and combinatorial synthesis and varying monomers, 
catalysts, initiators and end-cappers can result in a vast array of polymers 
with different chemical characteristic being synthesised (76).  There is 
great potential in heterogeneous nucleation and crystallisation of proteins 
in the presence of polymeric surfaces given that systems have now 
become automated and high throughput characterisation techniques are 
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being developed, in comparison to the first manual combinatorial polymer 
synthesis over a decade ago (77, 78).  These scientific advances point to a 
potential future where polymeric film libraries can be employed as another 
factor when screening for the appropriate crystallisation conditions of a 
protein, or for crystallising different protein forms. 
Further advantages in the use of polymer-induced heteronucleation were 
observed when research was conducted on the crystallisation of the 
proteins concanavalin A and hen egg-white lysozyme (HEWL), in the 
presence of polymeric films containing ionisable groups, cross-linked 
gelatine films with adsorbed poly-L-lysine or entrapped poly-L-aspartate, 
and silk fibroin with entrapped poly-L-lysine or poly-L-aspartate.  Results 
showed that the presence of ionisable groups on the film surface affected 
protein crystallisation.  From siliconised surfaces to uncharged polymeric 
surfaces to charged polymeric surfaces, there was a decrease in the 
induction time and protein concentration necessary for crystal nucleation 
to occur; while an increase in nucleation density was observed (40). 
Another form of polymer-induced heterogeneous nucleation is the use of 
imprinted polymeric surfaces for the selective nucleation of crystals.  
Molecular imprinting is defined DV ³the construction of ligand selective 
recognition sites in synthetic polymers where a template (atom, ion, 
molecule, complex or a molecular, ionic or macromolecular assembly, 
including micro-organisms) is employed in order to facilitate recognition 
site formation during the covalent assembly of the bulk phase by a 
polymerisation or polycondensation process, with subsequent removal of 
some or all of the template being necessary for recognition to occur in the 
spaces vacateGE\WKHWHPSODWLQJVSHFLHV´ (79).   
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Initially, imprinted surfaces were used for the crystallisation of inorganic 
molecules.  Copolymers, which were first imprinted with either calcium 
oxalate monohydrate or calcium oxalate dihydrate template crystals, were 
used to crystallise calcium oxalate from pure aqueous solutions and urine 
(80), demonstrating the use of imprinted surfaces for 
extraction/purification purposes.  Other work showed that polymeric 
surfaces, imprinted with calcite, successfully directed the crystallisation of 
calcium carbonate into calcite crystals, while the crystallising conditions 
would normally yield aragonite crystals, a polymorph of calcium carbonate 
(81) (Figure 1.7).  
 
 
 
 
Figure 1.7. Selective crystallisation of calcium carbonate, in the form of calcite 
crystals, using molecularly imprinted surfaces.  (a) The template rhombohedral calcite 
crystals form non-covalent bonds with the monomers, followed by cross-linking of monomers 
leading to the formation (b) of an imprinted surface.  (c) Removal of calcium carbonate by 
mild acid wash exposes the imprinted sites.  (d) Incubation of polymer surfaces with calcium 
and carbonate ions nucleates calcite only in the imprint sites under conditions which favour 
the formation of another polymorph of calcium carbonate, that of aragonite (81).  
Recently, the principle of polymer-based imprinted surfaces employed in 
the crystallisation of inorganic molecules, has evolved into the creation 
and utilisation of protein-imprinted polymers, as heteronucleants, to direct 
protein crystallisation and avoid protein precipitant formation.  Matsunaga 
et al. (82)  successfully created protein-imprinted polymer films.  Acrylic 
acid was utilised as the functional monomer in the creation of the 
imprinted polymer, while lysozyme was used as the template protein.  
After the removal of the template protein crystals, more lysozyme was 
successfully crystallised upon the polymer imprinted surface.  The 
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effectiveness of protein-imprinted polymers was further tested by the 
previously mentioned group, by successfully crystallising five out of the six 
proteins tested (83).   Moreover, Saridakis et al. (56) demonstrated the 
potential of molecularly imprinted polymer mediated protein crystallisation 
by crystallising proteins in the presence of polymer imprints under 
conditions which would normally yield no protein crystals.  The formation 
of large single protein crystals and faster overall crystal formation were 
observed in the presence of protein imprinted polymers. 
While all of the above mentioned work shows the clear potential in 
polymer mediated crystallisation, it is obvious that there is a great need 
for a clearer understanding of the mechanisms employed in polymer 
mediated heterogeneous protein crystallisation, which can be achieved via 
detailed surface analysis of the polymers and further experimental work 
with a broader range of challenging proteins, such as membrane proteins 
and other proteins which have yet to be successfully crystallised and 
characterised. 
 
1.7. Proteins Utilised in the Thesis 
Mutant human thioredoxin and wild type hen egg-white lysozyme (HEWL) 
were the two proteins used, for crystallisation, during this research.  
Thioredoxins are small (12 kDa) ubiquitous enzymes found in a variety of 
organisms, from archaea to humans.  Lack of cytosolic thioredoxin is lethal 
to mammals.  Thioredoxins are disulphide reductase enzymes that have a 
dithiol/disulphide active site.  All thioredoxins have the same overall three-
dimensional structure, known as the thioredoxin fold.  This consists of five 
ǃ-sheets surrounded by four Į-helices and the conserved active site 
sequence is Trp-Cys-Gly-Pro-Cys (84, 85). 
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Thioredoxins, via thiol redox control, facilitate the redox regulation of 
protein function and signalling.  In other words, thioredoxins maintain 
cytosolic proteins in their reduced state, while transcription factors, such 
as NF-kB, require thioredoxin reduction in order to bind to DNA (86).  In 
turn, thioredoxin is reduced by electrons from NADPH via thioredoxin 
reductase (87).  To date, structures of thioredoxins, wild type and mutant, 
from various organisms, have been obtained in solution by NMR (88, 89), 
as well as by X-ray diffraction of thioredoxin crystals (90, 91) (Figure 1.8). 
 
 
 
 
 
 (a)          (b) 
Figure 1.8. Human thioredoxin structures, at 0.70 Å resolution, obtained by crystal 
X-ray diffraction data. The (a) asymmetric unit (smallest portion of the crystal structure to 
which symmetry operations can be applied in order to create a complete unit cell, i.e. the 
crystal repeating unit) RI WKLRUHGR[LQ FRQVLVWV RI ILYH ǃ-VKHHWV DQG IRXU Į-helices with an 
active site of cysteines 32 and 35 in their oxidised form. The (b) assumed biological 
macromolecule, which is the assumed functional form of the protein, is a homodimer (two 
copies of the same asymmetric unit), which blocks the active site (85).  
Lysozyme is a 129 amino acid long, single chain, enzyme protein.  It is 
present in tears, saliva, mucus and in the egg-white of chickens.  
Lysozyme is a hydrolase and acts as a natural antibiotic by catalysing the 
hydrolytic cleavage of polysaccharides in the cell walls of bacteria, leading 
to bacterial lysis.  Specifically, lysozyme hydrolyses the glycosidic bond 
between N-acetylmuramic acid and N-acetyl-D-glucosamine, and lyses 
gram positive bacteria, which have a peptidoglycan layer as their outer cell 
wall.  Lysozyme has a molecular weight (Mw) of 14.3 kDa, four disulphide 
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bridges and is positively charged with a negatively charged active site 
FUHYLFHIRUPHGE\Į-helices, where the polysaccharide substrate binds to 
be hydrolysed. 
 
 
 
 
 
 
Figure 1.9. Hen egg-white lysozyme (HEWL) biological molecule structure, at 0.65 Å 
resolution, obtained by crystal X-ray diffraction.  Lysozyme is a hydrolase that is 
IRUPHG E\ Į±helices where polysaccharide substrates bind to be hydrolysed.  The HEWL 
structure shown above was crystallised along with ligand molecules (acetate ions, 1,2-
ethanediol and nitrate ions), which can be seen surrounding the single chain protein (92).  
Lysozyme was utilised in this research as it is the most studied 
crystallisation system.  This is due to the fact that HEWL is easily purified 
as well as being commercially available.  Moreover, lysozyme crystallises 
with little effort and usually affords crystals within hours to a few days.  
HEWL has five structurally characterised crystal forms: monoclinic, 
triclinic, hexagonal, orthorhombic and tetragonal, as well as a less 
characterised form, that of needles (23).  Finally lysozyme crystals afford 
high resolution X-ray diffraction patterns, with the highest resolution 
structure of 0.65 Å being published in 2007 (Figure 1.9) (92).  Thus far, 
polymers have been used as heterogeneous nucleants as well as 
precipitants during HEWL crystallisation (23, 56, 93). 
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1.8. Aims and Objectives 
In summary, predicting and controlling nucleation rates, or the occurrence 
of crystallisation, remains an elusive goal.  The aim of this project is the 
utilisation of polymers in order to predict, screen and direct protein 
crystallisation.  Polymers can be used as heterogeneous nucleants, in the 
form of films (adsorbed or plasma polymerised) or in solution.  The 
polymeric surfaces require having a complementary surface chemistry to 
that of the target protein, in order to act as successful heteronucleants 
during the crystallisation of the target protein (Figure 1.5).  Moreover, 
polymers can be utilised in order to aid in predicting, screening and 
directing protein crystallisation.  The objective thus far has been to 
research the effect of polymer surfaces and polymers in solution to 
promote heterogeneous nucleation of known protein crystallisation 
systems.   
Mutant human thioredoxin and hen egg-white lysozyme (HEWL) were used 
as model protein crystallisation systems in this research.  Polyacrylic acid 
(PAA), polyvinyl alcohol (PVOH) and polyallylamine (PAAm) were used in 
protein crystallisation experiments due to their different functional groups.  
The above mentioned polymers were used, as physically adsorbed 
polymeric films and as precipitants in solution, during protein 
crystallisation.  Surfaces were polymerised with acrylic acid (ppAA), allyl 
alcohol (ppAOH) and allylamine (ppAAm) in order to form substrates with 
similar functional groups to PAA, PVOH and PAAm respectively. 
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CHAPTER 2 
2. Experimental and Characterisation Techniques 
2.1.  Introduction 
The purpose of this chapter is to briefly introduce the theory behind the 
experimental and characterisation techniques that were employed in this 
research.  Surface characterisation techniques, such as Water Contact 
Angle (WCA), Atomic Force Microscopy (AFM) and X-ray Photoelectron 
Spectroscopy (XPS) were utilised for the analysis of the substrates 
produced.  Optical microscopy and X-ray crystallography were employed 
for protein crystal characterisation. 
 
2.2. Experimental Techniques 
2.2.1. Piranha Etching 
Piranha etching, (also known as: Piranha solutioQ RU &DUR¶V DFLG RU
permonosulphuric acid or peroxymonosulphuric acid), was first prepared 
by Heinrich Caro in 1898.  It is a mixture of sulphuric acid and hydrogen 
peroxide, of a 3:1 ratio, which can be utilised to clean substrate surfaces 
from organic residues.  The Piranha acid is a powerful oxidant and can 
react explosively with certain organic compounds.  Once hydrogen 
peroxide is added in sulphuric acid a self-starting, exothermic reaction 
takes place.  A second type of Piranha solution exists, which utilises 
ammonium hydroxide with hydrogen peroxide (3:1 ratio), however this is 
not a self-starting UHDFWLRQDQGUHTXLUHVKHDWLQJWRÛ&IRUWKHUHDFWLRQ
to occur.  This base Piranha solution is utilised when the substrates 
treated have a low tolerance to acids.   
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Piranha etching removes organic contaminants and oxidises the heavy 
metal salts present as contaminants on the surface of glass substrates, 
resulting in a chemicDOO\FOHDQDQGWRSRJUDSKLFDOO\µVPRRWK¶ surface, which 
can be assessed using Atomic Force Microscopy (AFM) (section 2.3.2).  
The surface chemistry change of Piranha etched glass can be assessed by 
taking Water Contact Angle (WCA) (section 2.3.1) measurements and 
conducting X-ray Photoelectron Spectroscopy (XPS) (section 2.3.3) on the 
substrates. 
When planning to utilise plasma polymerised glass substrates in protein 
crystallisation experiments it is prudent to ensure that the glass surfaces 
are efficiently cleaned so that contaminants do not affect the 
crystallisation results.  The topographical change following treatment with 
Piranha solution also ensures that a smooth and even plasma polymer 
deposition can take place.   
 
2.2.2. Plasma Polymerisation 
Figure 2.1 provides a schematic illustration of a plasma deposition 
chamber.  In the chamber during operation, a monomer is subjected to an 
electromagnetic field under low pressure.  The electrical discharge causes 
electrons to flow and interact with the monomer leading to the activation 
of the monomer.  The ionised gas created, which is also known as plasma, 
reacts with the substrate forming a highly cross-linked, polymer-like 
material, known as the plasma polymer, on the substrate surface.  The 
structural difference between conventional polymers and plasma polymers 
can be seen in Figure 2.2.   
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Figure 2.1. Schematic of a plasma deposition chamber.  During operation, a monomer 
is subjected to an electromagnetic field under low pressure within the main chamber.  The 
electrical discharge causes electrons to flow and interact with the monomer leading to the 
activation of the monomer.  The ionised gas created (plasma), reacts with the substrate 
forming a highly cross-linked, polymer-like material, known as the plasma polymer, on the 
substrate surface.  
 
 
 
 
 
 
 
Figure 2.2. Schematic demonstrating the structural difference between 
conventional and plasma polymers.  
Plasma polymers are employed in a range of applications due to the fact 
that they provide great coating adhesion on most substrates and exhibit 
chemical, mechanical as well as thermal stability.  In this research they 
were utilised since they provide a uniform chemistry across the treated 
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surface, with different functional groups depending on the monomer used; 
and should provide a stable enough coating for protein crystallisation to 
occur.  Figure 2.3 shows the three plasma polymerised substrate types 
used in this research.  At this point it should be noted that prior to plasma 
polymer deposition, substrates were usually treated with an inert gas, in 
this case oxygen, which is also ionised in order to create an etching 
plasma in order to further clean and prepare the substrates¶ surfaces. 
Surfaces were polymerised with acrylic acid (ppAA), allyl alcohol (ppAOH) 
and allylamine (ppAAm) in order to form substrates with similar functional 
groups to PAA, PVOH and PAAm respectively, which were used in protein 
crystallisation as physically adsorbed polymers and as polymers in 
solution. 
 
 
 
 
 
 
Figure 2.3. Schematic showing the preparation of the three types of plasma 
polymerised surfaces: (ppAA) plasma polymerised acrylic acid, (ppAAm) plasma 
polymerised allylamine and (ppAOH) plasma polymerised allyl alcohol.  
 
2.3. Surface Characterisation Techniques 
2.3.1. Water Contact Angle 
7KHFRQWDFWDQJOHǇLVDTXDQWLWDWLYHPHDVXUHRIWKHZHWWLQJRIDVROLGE\
a liquid, usually water, and it is a technique that is broadly accepted for 
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material surface analysis related to adhesion and absorption.  It is defined 
geometrically as the angle formed by a liquid at the three phase boundary 
where a liquid, gas and solid intersect. 
 
 
 
 
Figure 2.4. 6FKHPDWLFGHPRQVWUDWLQJKRZWKHLQWHUQDODQJOHǇRIDZater droplet 
can change depending on the interaction between water molecules and a solid 
surface. Hydrophilic surfaces attract the water molecules resulting in decreased internal 
DQJOHV ǇÛ ZKLOH K\GURSKRELF VXUIDFHV UHVXOW LQ ZHDNHU DWWUDFWLRQV ZLWK WKH ZDWHU
PROHFXOHVDQGKLJKHULQWHUQDODQJOHVǇ!Û  
In this research, water contact angles (WCA) were measured at room 
temperature using a contact angle goniometer.  WCAs were recorded so as 
to determine the substrate surfaces in terms of their 
hydrophobicity/hydrophilicity, following chemical treatment such as 
Piranha etching, which affects the nature of the substrate surface 
chemistry.  Figure 2.4 demonstrates the droplet spreading that occurs 
when water comes in contact with a hydrophilic surface, resulting in 
ǇÛEHLQJREVHUYHGZKLOHK\GURSKRELFVXUIDFHV WHQGWRKDYHDǇ!Û
when measured. 
 
2.3.2. Atomic Force Microscopy 
Atomic Force Microscopy (AFM) is a high resolution scanning probe 
microscopy.  In contrast to traditional microscopy, in AFM there is a direct 
mechanical contact between the probe and the surface that is being 
sampled/scanned at the time, as it can be seen in Figure 2.5. 
 
Ǉ Û Ǉ Û Ǉ!Û
Hydrophilic Hydrophobic
CHAPTER 2 Experimental and Characterisation Techniques 
32 
 
 
 
 
 
 
 
Figure 2.5. Schematic of the components in an Atomic Force Microscope (AFM).  AFM 
utilises a sharp probe, which is a tip on the end of a cantilever, moving over the surface of a 
sample in a raster scan.  The cantilever bends in response to the force between the tip and 
the sample.  The movements of the cantilever tip are detected by a beam deflection system, 
ZKHUHDODVHUEHDPJHWVGHIOHFWHGXSRQWKHFDQWLOHYHU¶VHQGDQGLVGHWHFWHGE\DSKRWRGLRGH  
Like all other scanning probe microscopes, the AFM utilises a sharp probe 
moving over the surface of a sample in a raster scan.  In the case of the 
AFM, the probe is a tip on the end of a cantilever which bends in response 
to the force between the tip and the sample.  The movements of the 
cantilever tip are detected by a beam deflection system, where a laser 
EHDP JHWV GHIOHFWHG XSRQ WKH FDQWLOHYHU¶V HQG Dnd is detected by a 
photodiode. AFM can be used for topographic measurements, 
measurements of attractive and repulsive forces between the probe tip 
and the sample surface, and measurements of the mechanical properties 
of the sample.  AFM can image almost any type of surface including 
polymers, ceramics, glass and even biological samples. 
In this thesis, AFM was used to image the topography of glass substrates 
at various stages of their treatment, from Piranha etching all the way to 
their plasma polymerised condition, prior to their use as heteronucleant 
surfaces in protein crystallisation. 
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2.3.3. X-ray Photoelectron Spectroscopy 
X-ray Photoelectron Spectroscopy (XPS) is a quantitative surface 
chemistry technique that analyses the top 10 nm of a sample surface.  
Due to the fact that XPS is a highly sensitive surface technique, even the 
smallest amount of contamination, such as a single fingerprint, can 
alter/mask the surface chemical composition of a sample.   
 
 
 
 
 
 
 
Figure 2.6. Schematic of the photoelectron emission in X-ray Photoelectron 
Spectroscopy (XPS) as a result of sample surface irradiation.  
Under ultra-high vacuum the sample is irradiated using an X-ray source, in 
this case a mono-FKURPDWHG $O NĮ VRXUFH  eV), causing 
photoelectrons to be emitted from the sample surface (Figure 2.6).  An 
energy analyser determines the binding energy of each of the 
photoelectrons collected by an electron collection lens.  The binding 
energy along with the intensity of the photoelectron peak detected is used 
to determine the identity, chemical state and quantity of the elements 
present upon the sample surface.  Since the photoelectrons released, 
following irradiation of the sample, can result in a positive charge built-up 
along the sample surface, a charge neutraliser filament above the sample 
ĭ Kǌ 
X-ray 
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gives a flux of low energy electrons providing uniform charge 
neutralisation. 
 
 
 
 
 
 
Figure 2.7. Schematic of the components of an X-ray Photoelectron Spectroscopy 
(XPS) system.  Under ultra-high vacuum the sample is irradiated using an X-ray source 
causing photoelectrons to be emitted from the sample surface.  An energy analyser 
determines the binding energy of each of the photoelectrons collected by an electron 
collection lens.  The binding energy along with the intensity of the photoelectron peak 
detected is used to determine the identity, chemical state and quantity of the elements 
present upon the sample surface.  
Figure 2.7 is a schematic of the main components of an XPS system, such 
as the one used in this research.  As a surface chemistry analysis 
technique, XPS is ideal for contaminant detection, and was used to analyse 
glass substrates that were Piranha etched, oxygen etched and plasma 
polymerised with different monomers, prior to their use as heteronucleant 
surfaces in protein crystallisation.   
 
2.4. Protein Crystal Characterisation Techniques 
2.4.1. Optical Microscopy 
An optical stereomicroscope, which uses visible light and a system of 
lenses, was employed to quantitatively observe the crystallisation trays 
used in this research.   
Isotropic materials, such as glass and sodium chloride crystals, have an 
index of refraction that is equal throughout their structure, as their 
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mechanical properties have identical values in all directions.  However, 
most physical properties of a wide variety of crystals, including liquid and 
macromolecular crystals, show variation throughout their structure.  This 
anisotropy in the optical properties of crystals is known as birefringence.  
A birefringent material will cause a light ray to split into two beams as it 
passes through it.  Protein crystals can be viewed under a light microscope 
with polarising optics in order for birefringence to be observed and to be 
able to differentiate between protein crystals (birefringent) and non-
birefringent crystal salts/amorphous precipitate. 
The attachment of a polarising filter to the optical stereomicroscope (cross 
polar microscopy) was used to confirm the presence of birefringent protein 
crystals (instead of salt crystal formation) as a primary qualitative 
technique.  Lysozyme and thioredoxin crystals are both coloured when 
viewed via cross polar microscopy, while isotropic salt crystals appear 
clear.  A digital camera attached to the microscope was used to image the 
crystals and obtain photomicrographs of the crystallisation wells.  
 
2.4.2.  X-ray Crystallography 
X-ray crystallography is a common protein crystal characterisation 
technique, used to determine the arrangement of atoms within a crystal.  
A schematic overview of x-ray crystallography can be seen in Figure 2.8.   
In x-ray crystallography, electrons, from an x-ray source, hit a copper 
target to produce a primary x-ray beam.  The x-ray beam hits the sample 
crystal, which is mounted on a goniometer and is gradually rotated.  The 
diffracted x-rays are detected electronically and by collecting these two-
dimensional diffraction patterns, from various angles of the sample crystal, 
it is possible to convert the information into a three-dimensional map of 
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the electron density of the crystal.  Using computational calculations it is 
then possible to extrapolate a probable three-dimensional structure for the 
target molecule crystallised.  In this research, x-ray diffraction patterns 
were obtained from the protein crystals produced in order to confirm their 
identities, as their protein structure has already been researched and 
elucidated. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8. Schematic overview of X-ray crystallography.  Electrons hitting a copper 
target create a primary x-ray beam which is diffracted by a crystal.  The diffracted x-rays 
strike an electronic detector and create an x-ray diffraction pattern.  Computational 
calculations are performed in order to create an electron density map.  Finally, a three-
dimensional structural rendering of the crystal is then predicted (tertiary structure of human 
thioredoxin shown above was obtained by Weichsel et al. (85)).  
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CHAPTER 3 
3. Materials and Methods 
3.1. Physically Adsorbed Polymers and Protein Crystallisation 
3.1.1. Preparation of Polymer Blends 
PAA ~50 kDa (25% in H2O) was purchased from Polysciences, PVOH ~55 
kDa was purchased from Aldrich and PVP ~72 kDa was purchased from MP 
Biomedicals (Figure 3.1).  HPLC grade methanol (MeOH) was obtained 
from Fisher Scientific.  Polymer solutions of PAA in water (H2O), PVOH in 
H2O and PVP in MeOH were prepared at a 1% w/v concentration.  Using 
these polymer solutions, polymer blends of PAA with PVOH, PAA with PVP, 
and PVP with PVOH were prepared in v/v ratios of 0:10, 1:9, 2:8, 3:7, 4:6 
5:5, 6:4, 7:3, 8:2, 9:1 and 10:0.  Thus, twenty-seven polymer blends and 
three pure polymer solutions were prepared, each with a total volume of 
100 µl.  All the solutions were centrifuged at 13,000 rpm for 5 min at 4oC.  
 
 
 
Figure 3.1. Chemical structures of polyacrylic acid (PAA), polyvinyl alcohol (PVOH) 
and polyvinyl pyrrolidone (PVP).  
 
3.1.2. Preparation of Crystallisation Plate ± Method I 
Art Robbins Intelli-PlateTM 96-2 well crystallisation plate is commercially 
available from Hampton Research (Figure 3.2).  For each polymer solution 
(prepared in section 3.1.1) 8 µl aliquots were manually pipetted into the 
large sample wells of the crystallisation plate, in triplicate for 
reproducibility.  Each corresponding small sample well contained no 
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polymer and was used as a control.  Three large sample wells and their 
corresponding small wells were also kept polymer-free for control 
purposes.  Two plates were prepared, one for each protein crystallisation 
protocol. 
 
 
 
 
Figure 3.2. Rendering of the Art Robbins Intelli-PlateTM 96-2 well crystallisation 
plate.  It is made out of polystyrene and has 96 reservoir wells (100 µl max fill volume) with 
two different size corresponding sample wells (10 µl and 4 µl max fill volume).  Commercially 
available from Hampton Research.  
The crystallisation plates were loosely covered with aluminium foil and the 
solvents of the polymer solution drops were left to evaporate completely 
at room temperature (RT) (~2 h). 
 
3.1.3. Crystallisation Protocol for Human Thioredoxin Trigonal 
Crystals 
Mutant human thioredoxin, (Cys35 and Cys73 mutated to Ser35 and Arg73 
respectively, pI: 4.97), 60 mg/ml in a buffer of 20 mM TRIS-HCl, 150 mM 
NaCl, pH 7.4, was kindly provided by Dr Gareth Hall and was centrifuged 
at 13,000 rpm for 5 min at 4oC.  0.1 M sodium acetate, 30% v/v PEG 300, 
pH 4.6 buffer was prepared and filtered through a 0.2 µm cellulose acetate 
membrane filter. 
Thioredoxin crystallisation was performed on a 96-2 well crystallisation 
plate (prepared in section 3.1.2) that contained polymer blend films, using 
the sitting drop vapour diffusion technique.  Specifically, protein solution 
(1 µl) and buffer (1 µl) were aliquoted into each sample well (large and 
Large sample well 
Reservoir well 
Small sample well 
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small) and 48 µl of buffer were aliquoted in each reservoir well of the 
crystallisation plate.  The final concentration of thioredoxin in each sample 
well was 30 mg/ml.  All sample wells containing PAA turned opaque when 
protein and buffer solutions were aliquoted into them.  The plate was then 
sealed and incubated at 19oC.  Crystals started forming after 13 days. 
 
3.1.4. Crystallisation Protocol for Tetragonal HEWL Crystals ± 
Method I 
HEWL was purchased from Sigma (catalogue number: L6876, EC: 
3.2.1.17, pI: 11.35, lysozyme activity: ~50,000 units/mg protein).  0.1 M 
sodium acetate solution at pH 4.8 was prepared and filtered through a 0.2 
µm cellulose acetate membrane filter.  This was used to prepare the 50 
mg/ml HEWL solution, which was then centrifuged at 13,000 rpm for 5 
min at 4oC.  0.1 M sodium acetate, 8% w/v NaCl, pH 4.8 buffer was 
prepared and filtered through a 0.2 µm cellulose acetate membrane filter.  
HEWL crystallisation was performed on a 96-2 well crystallisation plate 
(prepared in section 3.1.2) that contained polymer blend films, using the 
sitting drop vapour diffusion technique.  Specifically, protein solution (2 µl) 
and buffer (2 µl) were aliquoted into each sample well (large and small) 
and 46 µl of buffer were aliquoted in each reservoir well of the 
crystallisation plate.  The final concentration of HEWL in each sample well 
was 25 mg/ml.  All sample wells containing PAA turned opaque when 
protein and buffer solutions were aliquoted into them.  The plate was then 
sealed and incubated at 19oC.  Crystals formed within 24 h. 
NB: When sealing the plate, the drops of protein and buffer contained 
within the small sample wells of the crystallisation plate, tended to touch 
the sealing tape.  Thus, from then on the total volume aliquoted in all 
sample wells was not more than 2 µl. 
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3.1.5. Preparation of Polymer Solutions 
PAA ~50 kDa (25% in H2O) and PAA ~1,000 kDa were purchased from 
Polysciences.  PAA ~100 kDa (35% in H2O), PAA (~0.1% cross-linked) 
~3,000 kDa and PAA (~0.1% cross-linked) ~4,000 kDa were purchased 
from Sigma. 
The following polymer solutions were prepared: PAA (~50 kDa) in H2O at 
concentrations of 0.01%, 0.1%, 1%, 1.5%, 2.0%, 2.5%, 3%, 3.5%, 4%, 
4.5%, 5% (w/v); PAA ~100 kDa in H2O at concentrations of 0.1% and 1% 
(w/v); PAA ~1,000 kDa in H2O at concentration of 0.1% (w/v); PAA 
~3,000 kDa in H2O at concentration of 0.1% (w/v); and PAA ~4,000 kDa 
in H2O at concentration of 0.1% (w/v).  All polymer solutions were 
centrifuged at 13,000 rpm for 5 min at 4oC. 
 
3.1.6. Preparation of Crystallisation Plate ± Method II 
In order to avoid contamination, the Art Robbins Intelli-PlateTM 96-2 well 
crystallisation plate (Figure 3.2) preparation was conducted in a laminar 
flow cabinet.  For each polymer solution (prepared in section 3.1.5) 8 µl 
aliquots were manually pipetted into large sample wells of the 
crystallisation plate, in triplicate for reproducibility.  The solvent was left to 
evaporate completely at RT for 2 h.  Each corresponding small sample well 
contained no polymer and was used as a control.  Thirty-six large sample 
wells and their corresponding small wells were also kept polymer-free for 
control purposes.  
For the polymers solutions PAA ~100 kDa 0.1% in H2O, PAA ~1,000 kDa 
0.1% in H2O, PAA ~3,000 kDa 0.1% in H2O and PAA ~4,000 kDa. 0.1% in 
H2O, an extra set of 8 µl aliquots were manually pipetted into the large 
sample wells of the crystallisation plate, in triplicate.  The solvent was left 
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to evaporate completely at RT for 2 h.  This was repeated twice more, so 
that (8 µg/8 µl x 3=) 24 µg of PAA were deposited in each of these wells.  
This was done due to the fact that small volumes of high molecular weight 
polymer solutions were highly viscous.  
 
3.1.7. Crystallisation Protocol for Tetragonal HEWL Crystals ± 
Method II 
HEWL crystallisation was performed on a 96-2 well crystallisation plate 
(prepared in section 3.1.6) that contained PAA films, using the sitting drop 
vapour diffusion technique.  The same protocol was used as described in 
section 3.1.4, but with different volumes of protein and buffer being 
aliquoted.  The pipetting was conducted in a laminar flow hood to avoid 
contamination.  Specifically, 1 µl of protein (50 mg/ml HEWL in 0.1 M 
sodium acetate solution at pH 4.8) and 1 µl of buffer (0.1 M sodium 
acetate, 8% w/v NaCl, pH 4.8) were aliquoted into each sample well (large 
and small) of the crystallisation plate.  Also 48 µl of buffer were aliquoted 
in each reservoir well.  Each sample well had a HEWL concentration of 25 
mg/ml.  All sample wells containing PAA turned opaque when protein and 
buffer solutions were aliquoted into them.  The crystallisation plate was 
sealed and incubated at 19oC.  Crystals formed within 24 h.   
 
3.1.8. Solubility Test 
During the previous crystallisation experiments (sections 3.1.3, 3.1.4 and 
3.1.7) sample wells that contained PAA turned opaque following the 
addition of protein/buffer solution.  This could be due to PAA film 
delaminating or redissolving.  PAA is water soluble and the buffer (0.1 M 
sodium acetate, 8% w/v NaCl, pH 4.8) and protein solution (50 mg/ml 
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HEWL in 0.1 M sodium acetate solution at pH 4.8) used in HEWL 
crystallisation are aqueous solutions.   
Table 3.1 shows the concentration of the PAA aliquots pipetted into the 
crystallisation plate during the experiment described in section 3.1.6, prior 
to solvent evaporation, and the corresponding PAA concentration in each 
of the sample wells, provided that PAA redissolved completely in 2 µl of 
protein/buffer solution. 
Concentration of PAA 8 µl 
aliquots prior to solvent 
evaporation 
Concentration of redissolved PAA film in 2 
µl protein/buffer solution 
PAA 0.01%  (0.8 µg / 8 µl ї0.8 µg / 2 µl =0.4 µg/µl ) PAA 
0.04% 
PAA 0.1%  PAA 0.4% 
PAA 0.3% (= 0.1% x 3) PAA 1.2% 
PAA 1%  PAA 4% 
PAA 1.5%  PAA 6% 
PAA 2%t PAA 8% 
PAA 2.5%  PAA 10% 
PAA 3%  PAA 12% 
PAA 3.5%  PAA 14% 
PAA 4% PAA 16% 
PAA 4.5%  PAA 18% 
PAA 5%  PAA 20% 
 
Table 3.1. Concentration of the polyacrylic acid (PAA) aliquots pipetted into the 
crystallisation plate during the experiment described in section 3.1.6, prior to solvent 
evaporation, and the corresponding PAA concentration in each of the sample wells, provided 
that PAA redissolved completely in 2 µl of protein/buffer solution.  
Freeze-dried PAA ~50 kDa (400 mg) and freeze-dried PAA ~100 kDa (80 
mg) were weighed in two separate clear plastic 5 ml vials.  Buffer (1 ml) 
and protein solution (1 ml) were added in each vial (400 mg/2 ml ± PAA 
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20% and 80 mg/2 ml ± PAA 4%).  PAA ~1,000 kDa (48 mg), PAA (~0.1% 
cross-linked) ~3,000 kDa (48 mg) and PAA (~0.1% cross-linked) ~4,000 
kDa (48 mg) were weighted in three separate clear plastic 5 ml vials.  
Buffer (2 ml) and protein solution (2 ml) were added in each vial (48 mg/4 
ml ± PAA 1.2%).  All eight solutions turned cloudy during brief mixing.  
The PAA visually appeared to have dissolved in all solutions. 
 
3.1.9. Crystal Imaging 
Images of the crystals were obtained using a Leica MZ16 
Stereomicroscope (63x magnification), with a Leica CLS1 50X fan-cooled 
light source, connected to a Nikon Coolpix 4500 digital camera (4.0 
megapixels). 
 
3.2. Polymers as Precipitants and Protein Crystallisation 
3.2.1. Preparation of Stock Solutions 
The solubility test (section 3.1.8) showed that PAA of various molecular 
weights dissolves when mixed in protein and buffer solution used in the 
crystallisation protocol of HEWL.  Thus, it was necessary to observe 
whether PAA, of various molecular weights and concentrations, dissolved 
in the reservoir solution of the crystallisation protocol of HEWL would give 
similar results to experiment 3.1.7. 
These commercially available polymers, PAA ~50 kDa (25% in H2O), PAA 
~100 kDa (35% in H2O) and PAA ~1,000 kDa (see section 3.1.5 for 
materials), were used in order to prepare the following polymer solutions: 
PAA ~50 kDa 20% in H2O pH 4.8, PAA ~100 kDa 20% in H2O pH 4.8 and 
PAA ~1,000 kDa 1% in H2O pH 4.8.  The polymer solutions were then 
filtered using a 0.2 µm cellulose acetate membrane filter.  Also a stock 
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buffer solution of 0.25 M Na Acetate 20% NaCl pH 4.8 was prepared and 
filtered using a 0.2 µm cellulose acetate membrane filter.  
Using the above mentioned pH-altered polymer solutions and the stock 
buffer solution the following reservoir solutions were prepared at a final 
volume of 1 ml or 2 ml: PAA (~50 kDa) 0.02%, 0.08%, 0.2%, 0.8%, 2%, 
3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11% and 12% in 0.1 M sodium 
acetate 8% NaCl pH 4.8; PAA (~100 kDa) 0.02%, 0.08%, 0.2%, 0.8%, 
2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11% and 12% in 0.1 M 
sodium acetate 8% NaCl pH 4.8; and PAA (~1,000 kDa) 0.002%, 0.008%, 
0.02%, 0.08% and 0.2% in 0.1 M sodium acetate 8% NaCl pH 4.8.  
 
3.2.2. Crystallisation Protocol for Tetragonal HEWL Crystals± 
Method III 
HEWL crystallisation was performed on Art Robbins Intelli-PlateTM 96-2 
well crystallisation plates (Figure 3.2), using the sitting drop vapour 
diffusion technique.  The same protocol was used as described in section 
3.1.4, but with different volumes of protein and buffer being aliquoted.  All 
manual pipetting was conducted on an open lab bench.  Specifically, 50 µl 
of each of the reservoir solutions prepared in section 3.2.1 was aliquoted 
in triplicate in the reservoir wells of the crystallisation plates. 1 µl of 
protein (50 mg/ml HEWL in 0.1 M sodium acetate solution at pH 4.8) and 
1 µl reservoir solution taken from each reservoir were aliquoted into 
corresponding sample wells (big and small) of the crystallisation plate.  In 
each sample well, the PAA concentration was half of the polymer 
concentration in the reservoir, while HEWL concentration was 25 mg/ml.  
For control, some wells contained no polymer in their reservoir solution 
and some wells contained no protein.  All sample wells containing PAA 
turned opaque when protein and buffer solutions were aliquoted into 
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them.  The crystallisation plate was sealed and incubated at 19oC.  
Crystals formed within 24 h. 
 
3.2.3. Crystal Imaging 
Images of the crystals were obtained as described in section 3.1.9. 
 
3.3. Plasma Treated Surfaces and Protein Crystallisation 
3.3.1. Preparation of Plasma Polymers 
3.3.1.1. Piranha Etching 
HPLC grade acetone and hydrogen peroxide (30% in H2O) were purchased 
from Fluka (Sigma Aldrich). Sulphuric acid 95% laboratory reagent grade 
was purchased from Fisher Chemicals.  Prior to Piranha etching, glass 
cover slips (Scientific Laboratory Supplies Ltd, No. 2 thickness, 22 x 22 
mm) were washed using acetone and dried under a nitrogen stream.  The 
glass substrates were then immersed in Piranha solution of 3:1 (v/v) 
sulphuric acid / hydrogen peroxide for 30 min (exothermic reaction).  The 
substrates were then turned over and immersed in Piranha solution for 
another 30 min.  The substrates were then rinsed extensively under 
running deionised water, followed by drying under a nitrogen stream. 
 
3.3.1.2. Plasma Treatment 
Acrylic acid, allylamine and allyl alcohol were obtained from Aldrich.  They 
were used as received, save three freeze-thaw cycles to remove dissolved 
gases prior to use.  The substrates for plasma polymerisation (Scientific 
Laboratory Supplies Ltd glass cover slips, No. 2 thickness) were acetone 
washed and Piranha etched prior to plasma treatment.  The substrates 
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were placed in a plasma deposition reactor.  All substrates were first 
oxygen plasma etched for 5 min at 20 W incident power, ~300 mTorr 
pressure.  The plasma deposition parameters for plasma polymerised 
acrylic acid (ppAA) and allylamine (ppAAm) plasma were: 20 W power and 
300 mTorr pressure for ~28 min.  For the deposition of plasma 
polymerised allyl alcohol (ppAOH) the power was 100 W. 
 
3.3.2. Crystallisation Protocol for Tetragonal HEWL Crystals± 
Method IV 
HEWL crystallisation was performed on a VDX 24 well crystallisation plate, 
obtained from Hampton Research, using the sitting drop vapour diffusion 
technique.  Dow Corning vacuum grease was also purchased from 
Hampton Research.  The protocol for preparing the protein and buffer 
solutions is described in section 3.1.4.  All manual pipetting was conducted 
on an open lab bench.  500 µl of buffer was pipetted into each well.  1 µl 
of protein (50 mg/ml HEWL in 0.1 M sodium acetate solution at pH 4.8) 
and 1 µl of buffer solution were pipetted into each substrate (prepared in 
sections 3.3.1.1  and 3.3.1.2).   The substrate was then carefully inverted 
and using vacuum grease it was sealed over a well.  The HEWL 
concentration on each substrate was 25 mg/ml.  For control, plain glass 
was also used a substrate.  The crystallisation plate was incubated at 
19oC.  Crystals formed within 24 h.   
 
3.3.3. Crystal Imaging 
Images of the crystals were obtained as described in section 3.1.9. 
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3.3.4. Substrate Surface Characterisation 
3.3.4.1. X-Ray Photoelectron Spectroscopy 
XPS analysis was performed using a spectrometer the Kratos AXIS ULTRA 
with a mono-chromated Al kĮ X-ray source (1486.6 eV) operated at 15 
mA emission current and 10 kV anode potential.  The samples were 
inserted into the Ultra High Vacuum (UHV) chamber for analysis at a 
pressure of 10-9 Torr.  The spectrometer was used in FAT (fixed analyser 
transmission) mode, with pass energy of 80 eV for wide scans and pass 
energy 20 eV for high resolution scans.  The magnetic immersion lens 
V\VWHPDOORZHGWKHDUHDRIDQDO\VLVIRUWREHGHILQHGE\DSHUWXUHVDµVORW¶
DSHUWXUHRI[ǋPIRUZLGHVXUYH\VFDQVDQGKLJKUHVROXWLRQVFDQV
The take off angle for the photoelectron analyser was 90Û and acceptance 
DQJOHRIÛ. 
Electrons emitted from the top surface were taken through an 
electrostatic/magnetic lens system (Hybrid lens) and a hemispherical 
analyser (CHA).  For the non-conducting samples a charge neutraliser 
filament above the sample surface was used to give a flux of low energy 
electrons providing uniform charge neutralisation.  Data analysis was 
carried out using CASAXPS software with Kratos sensitivity factors.  The 
high resolution peaks were correct using the C1s scans (peaks set at 
285.0 eV) to correct for any sample charging (typically 4-5 eV). 
 
3.3.4.2. Atomic Force Microscopy (AFM) 
Cover slips (Scientific Laboratory Supplies Ltd No. 2 thickness) 11 x 11 
mm (cut to size) were Piranha etched and plasma treated prior to AFM. 
Each substrate was placed on a SPM specimen disc (Agar Scientific part 
No. F7003) using double sided carbon discs (Agar Scientific part No. 
G3347N). Tapping mode AFM was conducted using a Dimensions 3000 
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Atomic Force Microscope (Veeco, Sunnyvale) and a Tap300Al probe 
(Budget Sensors). 
 
3.3.4.3. Water Contact Angle Measurements (WCA) 
The contact angle measurements were performed using a goniometer CAM 
200 (KSV Ltd, Finland).  Liquid used to test the contact angle of the 
substrates was deionised water obtained through an ELGA purification 
V\VWHP ZLWK D PHDVXUHG UHVLVWLYLW\ RI  0ƻ  $ ZDWHU GURSOHW ZDV
placed from a needle onto the surface of the sample.  The complete drop 
profile at the solid-air interface was evaluated using Young-Laplace fit.  A 
manual baseline was placed on the image by the operator.  The contact 
angle was determined as the tangent of the drop profile at the 3 phase 
contact point.  The contact angle values obtained were the mean of the 
measurements taken at both sides of each water droplet.  At least four 
droplets were placed on the same sample at different locations.  A mean 
contact angle value was obtained for each sample. 
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CHAPTER 4 
4. Results 
4.1. Physically Adsorbed Polymers in Protein Crystallisation 
4.1.1. Protein Crystallisation 
Human thioredoxin and HEWL were crystallised, using the sitting drop 
vapour diffusion method.  The sample wells of the crystallisation plates 
were pre-coated with polymer blend films of PAA/PVOH, PAA/PVP and 
PVOH/PVP at various ratios.  In total, both proteins were crystallised 
utilising 30 different polymer surfaces, and in triplicate for reproducibility. 
 
 
 
 
 
 
 
Table 4.1. Table showing the occurrence of trigonal mutant human thioredoxin 
crystals on polymer blend films, in triplicate for reproducibility, ZKHUH¥ LQGLcates the 
formation of crystals and (-) indicates no crystals formed.  
For thioredoxin, the trigonal crystal-inducing protocol was used.  No 
crystals were formed in the presence of polymer blends of PAA/PVOH, and 
PAA/PVP.  Table 4.1 summarises the occurrence of human thioredoxin 
crystal formation, in the presence of the different polymer blend films.  
Photomicrographs of sample wells containing PAA/PVOH and PAA/PVP films 
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showed that the protein precipitated early on in the experiment, possibly 
due to increased nucleation, which can lead to protein aggregation. 
 
 
 
 
Figure 4.1. Photomicrographs showing trigonal mutant human thioredoxin crystals. 
Trigonal thioredoxin crystals were grown in the presence of polymer blend films and in their 
absence (controls). The trigonal thioredoxin crystal formed in (a) the presence of a polyvinyl 
pyrrolidone / polyvinyl alcohol (PVP/PVOH) blend of a 7/3 ratio, is similar in size to the 
thioredoxin crystal formed in (b) the control, which did not contain a polymer blend.  
Thioredoxin crystals started to appear after 13 days in the PVP/PVOH 
containing sample wells, as well as in the control sample wells (Figure 
4.1).  While surface poisoning was observed on some crystals, good sized 
thioredoxin crystals were formed overall (>250 µm largest dimension).  
The reliability of these results was problematic due to the lack of 
thioredoxin crystals in many control wells.  Overall, the results tentatively 
indicated to a potential use of PVP and PVOH surfaces as heterogeneous 
nucleants, however, the crystal growth rate was slow both in the absence 
and presence of PVP/PVOH polymer surfaces, as crystals formed over a 5 
month period. 
Further experiments concentrating on the crystallisation of thioredoxin in 
the presence of PVP and PVOH would be necessary, unfortunately, due to 
slow crystal growth rate, the mutant human thioredoxin protein was not 
utilised in further experiments in this research due to the time constraints 
of the project.  
HEWL was crystallised in the presence of polymer blend films of PAA/PVP 
and PAA/PVOH.  As the amount of PAA increased, in the composition of 
250 µm250 µm(a) (b)
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both polymer blends, there was a visible effect on the HEWL crystal 
formation (Figure 4.2).  Crystal aggregates were formed and the 
nucleation density of the HEWL crystals increased, as the size of the 
crystals decreased.  Finally, in the presence of only PAA, a glut of 
microcrystals formed along the surface of the sample wells.  
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Graph showing the size of hen egg-white lysozyme (HEWL) crystals in 
the presence of physically adsorbed polymer blends, using the following polymers: 
polyacrylic acid (PAA), polyvinyl pyrrolidone (PVP) and polyvinyl alcohol (PVOH).  Error bars 
represent mean ± standard deviation (n=3).  
In contrast, HEWL crystals formed in the presence of polymer blend films 
made of PVP/PVOH appeared similar in size to the HEWL crystals obtained 
in the controls, in the absence of polymers.  Some crystal surface 
poisoning was observed, which is the incorporation of impurities within the 
crystal structure, indicated by rough sections on the surfaces of the 
tetragonal HEWL crystals.  
0
20
40
60
80
100
120
140
160
180
0 1 2 3 4 5 6 7 8 9 10
C
ry
s
ta
l 
S
iz
e
 (
Pm
)
Polymer Blend Film Ratio
PAA:PVOH
PAA:PVP
: 10 : 9   : 8              : 7               : 6               : 5               : 4 : 3               : 2              : 1                : 0 
PVOH
PAA
PVP
250 µm
250 µm
250 µm
 
CHAPTER 4 Results 
52 
A solubility test showed that PAA can dissolve in the aqueous 
protein/buffer mixture used in the crystallisation experiments, provided 
that the mixture is agitated for a brief period of time.  However, the 
crystallisation plates were not subjected to rigorous agitation and most of 
the HEWL crystals formed along the surface of the sample wells.  This 
suggests that any PAA that remained in film form could have acted as a 
heterogeneous nucleant to the HEWL crystals, which were in contact with 
sample well surfaces. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Photomicrographs of hen egg-white lysozyme (HEWL) crystals grown in 
the presence of adsorbed polyacrylic acid (PAA) (casting solution concentrations).  
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In order to further observe the effect of PAA on HEWL crystallisation, 
higher molecular weight PAA was used (from ~50 kDa to ~4,000 kDa) and 
films of increasing concentration were created (Figure 4.3).  Given the PAA 
solubility in the protein/buffer HEWL crystallisation mixture, the increased 
molecular weight and concentration should have allowed for the majority 
of the PAA to remain in film form for a longer time, so it could act as a 
heterogeneous nucleant during HEWL crystallisation. 
Tetragonal HEWL crystals formed throughout the protein-buffer solution 
contained within the wells, in the presence of PAA ~50 kDa films created 
by low casting concentration solutions (0.01% and 0.1%), and were 
similar to the ones obtained in the controls, in the absence of PAA.  As the 
concentration of PAA increased, the number of crystals formed increased, 
the crystal size decreased to a few µm; and aggregates of microcrystals 
were observed.  Crystals were formed only at the surface of the sample 
wells, suggesting that, PAA films were acting as heterogeneous nucleants, 
lowering the nucleation energy barrier, resulting in the growth of multiple 
tetragonal HEWL microcrystals.  Finally at polymer casting solution 
concentrations of 3.5% to 5%, HEWL precipitated out of solution.  A 
similar effect was observed when PAA ~100 to ~4,000 kDa was used.   
 
4.1.2. X-ray Crystallography 
While cross polar microscopy confirmed that the crystals formed in the 
above mentioned experiments were protein crystals and not salt crystals, 
x-ray crystallography was also conducted on crystal samples in order to 
confirm that the crystallisation experiments yielded the desired results. 
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Figure 4.4. Diffraction pattern and summary of data collection statistics yielded by 
a single thioredoxin crystal.  
Figure 4.4 and Figure 4.5 illustrate the diffraction patterns of thioredoxin 
and HEWL crystals obtained following x-ray crystallography. 
 
 
 
 
 
 
 
 
Figure 4.5. Diffraction pattern and summary of data collection statistics yielded by 
a single hen egg-white lysozyme (HEWL) crystal.  
 
Summary of Data Collection Statistics
Space group P3121
Unit cell dimensions 62.11 Å  62.11 Å  90.68 Å
 ? ? ? ? ?ȗ90.00ȗ120.00ȗ
Resolution range (Å) 26.35  ?1.78 
Total number of 
reflections
58281
Number of unique 
reflections
19880
Average redundancy 2.93
Completeness (%) 99.7
Rmerge 0.043
Reduced Chi Squared 0.96
Summary of Data Collection Statistics
Space group P43212
Unit cell dimensions 78.60 Å  78.60 Å  36.93 Å
 ? ? ? ? ?ȗ90.00ȗ 90.00ȗ
Resolution range (Å) 21.37  ?1.78 
Total number of 
reflections
62933
Number of unique 
reflections
11554
Average redundancy 5.45
Completeness (%) 99.9
Rmerge 0.030
Reduced Chi Squared 0.99
Output (I/sigI) 38.1
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4.2. Polymers as Precipitants in Protein Crystallisation 
4.2.1. Protein Crystallisation 
The next step was to compare HEWL crystallisation in the presence of PAA 
in solution, acting as a precipitant, by dissolving PAA within the buffer 
mixture used in the crystallisation of HEWL (Figure 4.6).  The size of the 
crystals in the presence of PAA in solution decreased and the nucleation 
density increased.  However, these effects were not as pronounced as 
when PAA films were used during HEWL crystallisation, which resulted in 
multiple microcrystals being formed.  In addition, a different form of HEWL 
FU\VWDOV WKDW RI QHHGOHV ZLWK D µVHD-XUFKLQ¶ PRUSKRORJ\ formed at PAA 
concentrations of 5% to 6%, in solution.  This morphology of HEWL has 
been previously reported (94, 95). 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Photomicrographs of hen egg-white lysozyme (HEWL) crystals grown in 
the presence of polyacrylic acid (PAA) in solution as a precipitant (solution 
concentrations).  
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A similar effect on HEWL crystallisation was observed when PAA ~100 kDa 
was present in solution.  PAA concentrations of 3.5% to 6% resulted in 
concomitant formation of needle and tetragonal HEWL crystals, with 
reproducible (i.e. within all the sample wells) needle crystal growth at high 
concentrations.  Overall, PAA in solution, at relatively high concentrations, 
resulted in the growth of a different HEWL crystal form.  Needle crystals 
formed at a slower rate than tetragonal crystals.  Specifically, tetragonal 
crystals grew within 24 h, while needle crystals grew within 4 days.  
Needle crystal growth was more reproducible at high concentrations, when 
PAA ~100 kDa was present in solution.  
 
 
 
 
 
 
 
 
 
Figure 4.7. Photomicrographs of hen egg-white lysozyme (HEWL) crystals grown in 
the presence of polymers.  Polymers used include polyacrylic acid (PAA), polyallylamine 
(PAAm) and polyvinyl alcohol (PVOH), in solution (1% solution concentration), physically 
adsorbed (1% casting solution concentration), and plasma polymerised acrylic acid (ppAA), 
allylamine (ppAAm) and allyl alcohol (ppAOH).  Hydrochloric acid was added in PAAm; and 
potassium hydroxide was added in PVOH, in solution, in order to change the pH to 4.8 which 
was required for HEWL crystallisation.  
HEWL was also crystallised in the presence of polyallylamine (PAAm) and 
PVOH, in solution and as physically adsorbed films (Figure 4.7).  PAAm has 
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a pH of 11.58 and it is soluble in aqueous solutions such as the protein-
buffer mixture used in the crystallisation of HEWL.  As the polymer 
redissolved it changed the pH of the protein-buffer mixture from 4.8 to a 
more basic pH, causing the protein to precipitate instantly.  PAAm was 
also used in solution, without altering its pH, and it caused the protein to 
precipitate.  
However, when the pH of PAAm was altered to 4.8; by utilising a pH 
electrode and gradually adding hydrochloric acid, it created a cationic 
polyelectrolyte.  The PAAm hydrochloride salt was then used in solution 
during the crystallisation of HEWL and it resulted in tetragonal protein 
crystal formation at various depths of the crystallisation plate wells.  At 
low solution concentrations, (0.01% and 0.1%), the HEWL crystals were 
the same as those formed in the controls, in the absence of PAAm.  As the 
concentration of the salt increased the HEWL crystals showed surface 
poisoning.  From a concentration of 2.5% and above there was a 
concomitant formation of tetragonal and needle HEWL crystals.  
PVOH in solution and as physically adsorbed films caused surface 
poisoning of the tetragonal HEWL crystals.  Crystals grew at various 
depths within the crystallisation plate wells, and the size and nucleation 
density of the crystals appeared unaffected.  There was no concomitant 
formation of needle and tetragonal crystals, as the concentration of the 
SRO\PHU ZDV QRW DERYH  ERWK DV FDVWLQJ VROXWLRQ DQG µLQ VROXWLRQ¶
concentration). 
 
4.3. Plasma Treated Surfaces and Protein Crystallisation 
In order to avoid cast polymer films redissolving in the aqueous protein-
buffer mixture, it was necessary to look for polymers that had a similar 
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chemical functionality to the above mentioned polymers but had an 
alternative mechanism of attachment.  Plasma polymers are highly cross-
linked and are covalently linked to the substrate surface.  Figure 2.3 
illustrated the preparation stages of the glass substrates prior to their 
plasma polymerisation for the creation of heteronucleant polymer 
substrates to be utilised in protein crystallisation.  
 
4.3.1. Water Contact Angle 
Table 4.2 demonstrates how chemical treatments alter the glass substrate 
surface hydrophilicity.  Piranha etching, resulted in a highly hydroxylated 
surface which is very hydrophilic.  Oxygen etching further decreased WKHǇ
angle measured, where as the WCA measurements for each of the plasma 
polymerised surfaces matched previously recorded data (96) and were 
less hydrophilic.  
 
 
 
 
Table 4.2. Table containing Water Contact Angle (WCA) measurement of glass 
surfaces at various stages during the preparation of plasma polymerised 
substrates. 
4.3.2. Atomic Force Microscopy 
The topography of the glass substrates was also measured at the same 
stages as section 4.3.1, during their preparation prior to their use in 
protein crystallisation, following plasma polymer deposition.  A sample of 
AFM micrographs illustrating the changes in topography, especially 
following the Piranha etching treatment, can be seen in Figure 4.8. 
Unclean 
cover slip
Acetone 
washed 
cover 
slip
Piranha 
etched 
cover slip
Oxygen 
etched 
cover slip
ppAcrylic
acid
ppAllyla
mine
ppAllyl
alcohol
Mean 
contact 
angle
61.16Û 67.78Û 19.44Û 17.86Û 73.67Û 71.59Û 79.55Û
Standard 
deviation 
(±)
3.65Û 1.26Û 0.51Û 1.52Û 1.42Û 1.03Û 1.27Û
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Figure 4.8. Atomic Force Microscopy (AFM) micrographs of unclean glass (coverslip), 
acetone washed glass, piranha etched glass, oxygen etched glass, plasma polymerised acrylic 
acid (ppAA) and plasma polymerised allylamine (ppAAm) glass.  
Unclean Cover Slip 
Piranha Etched Cover Slip Oxygen Etched Cover Slip
Acetone Washed Cover Slip
ppAcrylic Acid ppAllylamine
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4.3.3. X-ray Photoelectron Spectroscopy 
Both wide survey and high resolution scans were obtained of sample 
surfaces at the same preparation stages as those in sections 4.3.1 and 
4.3.2.  The full set of data can be seen in appendix A. 
 
4.3.4. Protein Crystallisation 
Plasma polymerised acrylic acid (ppAA), allylamine (ppAAm) and allyl 
alcohol (ppAOH) were prepared and used in the crystallisation of HEWL 
(Figure 4.7).  Due to the preparation of the plasma treated surfaces, it 
was necessary to use hanging drop vapour crystallisation instead of the 
sitting drop vapour diffusion method used so far in the crystallisation of 
HEWL. 
The HEWL crystals formed on all surfaces were visible under a 
stereomicroscope (section 3.1.9) and were of uniform size (Figure 4.7).  
However, the use of ppAOH caused surface poisoning of the HEWL 
crystals.  The crystals were similar in size to the ones formed in the 
absence of polymers (~250-270 µm largest dimension), with clusters of 
HEWL crystals also observed in the presence of ppAOH (Figure 4.9).  In 
contrast, no surface poisoning was observed in the presence of ppAAm.  
However, crystal nucleation was affected, with large numbers of crystal 
clusters forming in the presence of ppAAm. 
Crystal clustering is observed when various surfaces were used, such as 
plain glass as well as cleaned glass (acetone washed, Piranha and oxygen 
etched glass).  In comparison, ppAA caused some surface poisoning but 
resulted in the formation of single tetragonal crystals, which are required 
in X-ray crystallography. 
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Figure 4.9. Graph showing the number of hen egg-white lysozyme (HEWL) crystals 
in the presence of various surfaces used in hanging drop vapour diffusion 
crystallisation.  All HEWL crystals were visible under a stereomicroscope and had a uniform 
size (~250-270 ǋPLQODUJHVWGLPHQVLRQError bars represent mean ± standard deviation 
Q  
The ability to crystallise proteins using the minimum amount possible is 
advantageous, as protein purification usually yields small quantities.  
When the protein concentration used was lowered, ppAA did not crystallise 
HEWL at concentrations lower than 12 mg/ml.  This agrees with published 
data where polymers were used as heterogeneous nucleants for HEWL 
(40). 
Finally, an experiment was conducted in order to see the effect of surface 
ageing on protein crystallisation.  Figure 4.10 shows how the water 
contact angle measurements of four different surfaces (plain, Piranha 
etched glass, oxygen etched glass, and ppAA), changed over a period of 5 
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days. The HEWL crystals appeared unaffected by the change in 
hydrophobicity/hydrophilicity. 
 
 
 
 
 
 
 
 
 
Figure 4.10. Graph showing the average water contact angle measurements of plain 
glass, Piranha etched and plasma treated surfaces over time.  The photomicrographs 
of hen egg-white lysozyme (HEWL) crystals grown on the various surfaces on day 1 and on 5 
days old surfaces, were included to demonstrate the uniform habit of the crystals. The HEWL 
crystals appeared unaffected by the hydrophobicity/hydrophilicity changes of the substrate 
surfaces caused by their aging.  Error bars represent mean ± standard deviation (n4).  
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CHAPTER 5 
5. Discussion, Conclusions and Future Applications 
5.1. Discussion of Physically Adsorbed Polymers and Protein 
Crystallisation 
The ultimate aim of this area of research is to predict and control protein 
crystallisation via the use of polymers as heteronucleants.  A first step 
towards this aim was to observe the effect of polymer surfaces on the 
crystallisation of proteins. 
The two proteins selected were HEWL and mutant human thioredoxin. 
HEWL crystallisation is widely studied while human thioredoxin is a slightly 
more challenging crystallisation system.  The polymers selected, PAA, PVP 
and PVOH, are commercially available.  In the past, PAA, PVOH and PVP 
have been used as polymeric precipitants in the crystallisation of proteins 
(93).  Furthermore, PAA has been used as a precipitant (93), as well as a 
heterogeneous nucleant in the crystallisation of HEWL (23).  In addition, 
PAA brush particles (97) and planar PAA brushes (98) have been known to 
have a high protein affinity in low ionic strength, unsaturated, protein 
solutions.  
During this research, mutant human thioredoxin was crystallised in the 
presence of polymer blend films.  Thioredoxin crystals formed after 13 
days in the presence of PVP, followed by crystal growth in the 
corresponding control sample wells.  Thioredoxin crystals nucleated and 
grew in the presence of PVP/PVOH polymer blend films and in control 
samples wells, in the absence of polymers.  This could be due to the 
polymer blend films made of PVP/PVOH acting as heterogeneous 
nucleants.  The polymer surfaces could potentially have lowered the 
energy barrier that prevents the ordered aggregation of macromolecules, 
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and induced the formation of ordered thioredoxin crystal nuclei, by 
adsorbing the protein molecules.  The partially immobilised protein 
molecules could have then formed ordered intermolecular interactions 
resulting in crystal nuclei.  
While reproducibility of the results is not ideal, as crystals did not form in 
all the controls, the crystal growth rate was slow both in the absence and 
presence of PVP/PVOH polymer surfaces, as crystals formed over a 5 
month period.  However, the results indicated that the thioredoxin crystal 
nucleation rate was increased in the presence of PVOH and PVP.  In 
general, nucleation that occurs at a faster rate, than in the absence of a 
polymer film, but has a growth rate which results in large crystals (>250 
µm largest dimension) suitable for X-ray diffraction analysis, is a desirable 
effect and bears further investigation. 
When considering the HEWL crystallisation results, microcrystal formation 
in the presence of PAA films could have been due to an increased number 
of nucleation sites forming, which in turn affects the size and quality of the 
crystals, as there is an inverse correlation between size and nucleation 
density.  The average size of tetragonal HEWL crystals waVRYHUǋP
when 20 or less nucleation sites were formed.  Inversely, multiple 
nucleation sites commonly resulted in smaller crystals.  
Overall, the nucleation appeared to be more affected by the presence of 
PAA, than by PVP and/or PVOH films.  It has been reported that, crystal 
formation under low-ionic strength conditions appears to proceed to 
completion more rapidly (99). 
Rapid crystallisation tends to result in smaller crystals.  At pH 4.8, PAA is 
almost non-ionic, with only partially deprotonated carboxylate groups, 
while lysozyme has a positive net charge (100).  Provided that PAA, which 
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is soluble in water, partially redissolved in the crystallisation solution, it 
could have lowered the dielectric constant of the solution, resulting in an 
increase of the effective distance over which protein electrostatic effects 
occurred, leading to protein aggregation and the formation of multiple 
crystal nuclei.  
Moreover, ionic interactions between the partially deprotonated 
carboxylate groups of PAA (pKa 4.5) and the exposed positively charged 
arginines and lysines of HEWL (pI 11.35) (Figure 1.5), at pH 4.8, may 
have led to anchoring of the HEWL molecules by the PAA film.  This can 
result in the formation of multiple nucleation sites, supporting the 
formation of multiple microcrystals. 
PAA films of high concentrations appeared to have caused protein 
molecules to immediately separate in the supersaturated solution and 
form kinetically favoured amorphous aggregates. The increased 
aggregation rate would have prevented the slow formation of ordered 
intermolecular interactions, which would have led to crystal nuclei 
formation and crystal growth. 
 
5.2. Discussion of Polymers as Precipitants and Protein 
Crystallisation 
PAA in solution acted as a precipitant and not as a heterogeneous 
nucleant, as crystals formed at different depths within the wells of the 
crystallisation plate, in comparison to the formation of crystals along the 
bottom of the wells in the presence of PAA films.  Polymers, such as PEG, 
are often used in protein crystallisation experiments.  PAA and PAAm, as 
precipitants in solution at high concentrations, PD\KDYHFDXVHGDµVDOWLQJ
RXW¶ Hffect during HEWL crystallisation.  This occurs when the ionic 
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strength is increased to the point where salt ions and protein molecules 
compete for solvent/water molecules to maintain their hydration layers 
and therefore their solubility.  To fulfil their electrostatic requirements, the 
protein molecules begin to self-associate (18).  7KLVµVDOWLQJRXW¶HIIHFWFDQ
explain the growth of a different HEWL crystal form, that of needles, in the 
presence of PAA and PAAm in solution.   
HEWL needle crystals have been previously observed under chloride (23, 
101), nitrate and thiocyanate (102) salt conditions.  In previous studies, 
this form of crystals has been grown in solutions with high salt 
concentrations (101, 102), and in the presence of acid-functionalised 
polymeric surfaces, such as cross-linked acrylic acid and methacrylic acid 
(23).  The growth rate of needle crystals is slower than that of tetragonal 
HEWL crystals.  The increased nucleation sites caused by the high 
concentration of precipitant in combination with the increased viscosity of 
these solutions, may have promoted the formation and growth of HEWL 
needle crystals.  This is supported by the formation of needle crystals in 
WKHSUHVHQFHRI3$$aN'DaN'DDQG3$$PDWKLJK µLQVROXWLRQ¶
concentrations. 
 
5.3. Discussion of Plasma Treated Surfaces and Protein 
Crystallisation 
The precipitation of HEWL in the presence of PAAm films was caused by 
the film redissolving in the solution and increasing the pH above the 
optimum levels, which are between pH 4.3 to 4.8.  Basic proteins, such as 
HEWL (pI 11.35) crystallise 0.5-3 pH units below their pI point while 
extreme values of pH do not contribute significantly to the successful 
crystallisation of proteins (17, 24).  When using ppAAm there was crystal 
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clustering with molecules being improperly ordered within the crystal 
lattice, leading to defects.  A possible way to avoid those clusters is to use 
a lower protein concentration during protein crystallisation. 
PVOH and ppAOH did not appear to affect protein crystallisation, aside 
from surface poisoning, which is where an impurity or foreign particle is 
incorporated within the crystal.  The impurity in turn improperly fits the 
crystal lattice and impacts the disposition of neighbouring molecules, 
which in turn produces strain that is subsequently propagated through the 
lattice (14).  
ppAA has been shown to favour single crystal growth.  In contrast to the 
partially deprotonated PAA films, the highly cross-linked plasma polymer 
had ester and ether groups due to the nature of the plasma polymer 
deposition (see Appendix A).  Thus it had a reduced ability to act as a 
hydrogen donor to the positively charged HEWL, which may explain why 
there were fewer nucleation sites, resulting in the formation of large single 
crystals.  Some deprotonated carboxyl groups of ppAA may have aided in 
HEWL crystallisation but the effect was not the same as when PAA was in 
the form of physically adsorbed films. 
Finally, it appears that drop shape, as indicated by the water contact 
angles of Figure 4.10, had no major effect to the crystallisation of HEWL.  
However, there is a possibility that growth rate may have been affected, 
though the crystal habit of HEWL appeared to be consistent with those 
formed in the controls. 
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5.4. Conclusions and Future Applications 
The hypothesis of this work was that polymers can direct crystal habit and 
polymorphism. The data presented here have shown that physically 
adsorbed PAA can direct crystal habit formation, while PAA and PAAm, as 
precipitants in solution at high concentrations, PD\KDYHFDXVHGDµVDOWLQJ
RXW¶Hffect during HEWL crystallisation resulting in the growth of a different 
form of HEWL crystal.   
The data presented here agree with published work where PAA, PVOH and 
PVP have been used as polymeric precipitants in the crystallisation of 
proteins (93).  Furthermore, PAA has been used as a precipitant (93), as 
well as a heterogeneous nucleant in the crystallisation of HEWL (23).  In 
addition, PAA brush particles (97) and planar PAA brushes (98) have been 
known to have a high protein affinity in low ionic strength, unsaturated, 
protein solutions.  
Future work could involve the creation of brushes, grafted from surfaces, 
with various functional groups such as carboxyl groups, their 
characterisation and use in protein crystallisation.  The ultimate goal would 
be to utilise protein-imprinted polymers as heteronucleants to a vast array 
of proteins, including membrane proteins which are difficult to crystallise.  
Detailed characterisation of those imprinted surfaces would aid in better 
understanding the mechanisms at work behind the already successful 
crystallisation work recently published (56, 83) in the area of polymer 
mediated protein crystallisation. 
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XPS Wide Scan Spectrum of Piranha Etched Substrate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data of Wide Scans of Piranha Etched Substrate 
 
 
Electrons 
of Atoms 
Detected 
 
Binding 
Energy 
Atomic Percentage 
Piranha 
Etched 
Wide 
Scan 1 
Piranha 
Etched 
Wide 
Scan 2 
Piranha 
Etched 
Wide 
Scan 3 
Average 
of 
Piranha 
Etched 
Wide 
Scans 
Standard 
Deviation 
(+/-) 
Si 2p 100.0 28.54 28.76 28.84 28.71 0.16 
B 1s 190.0 4.71 6.55 4.65 5.31 1.08 
C 1s 282.0 4.85 3.96 6.42 5.08 1.24 
K 2p 290.5 1.34 1.50 1.16 1.34 0.17 
N 1s 399.5 1.02 1.14 0.61 0.92 0.28 
Ti 2p 457.0 0.91 0.53 0.52 0.65 0.22 
O 1s 529.5 58.10 56.85 57.04 57.33 0.67 
Zn 2p 1020.0 0.29 0.30 0.30 0.30 0.01 
Na 1s 1069.5 0.24 0.41 0.45 0.37 0.11 
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XPS Wide Scan Spectrum of Oxygen Etched Substrate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data of Wide Scans of Oxygen Etched Substrate 
 
 
Electrons 
of Atoms 
Detected 
 
Binding 
Energy 
Atomic Percentage 
Oxygen 
Etched 
Wide 
Scan 1 
Oxygen 
Etched 
Wide 
Scan 2 
Oxygen 
Etched 
Wide 
Scan 3 
Average 
of 
Oxygen 
Etched 
Wide 
Scans 
Standard 
Deviation 
(+/-) 
Si 2p 100.5 28.40 28.45 29.00 28.62 0.33 
B 1s 190.0 5.07 4.55 3.97 4.53 0.55 
C 1s 282.5 6.60 0.29 0.28 2.39 3.65 
K 2p 290.5 1.48 6.43 5.86 4.59 2.71 
N 1s 399.0 1.27 1.44 1.28 1.33 0.10 
Ti 2p 457.0 0.61 1.35 1.02 0.99 0.37 
O 1s 529.5 55.84 0.69 0.66 19.06 31.85 
Zn 2p 1019.5 0.28 56.24 57.44 37.99 32.66 
Na 1s 1069.5 0.46 0.55 0.48 0.50 0.05 
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XPS Wide Scan Spectrum of ppAA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data of Wide Scans of ppAA 
 
 
Electrons 
of Atoms 
Detected 
 
Binding 
Energy 
Atomic Percentage 
ppAA 
Wide 
Scan 1 
PpAA 
Wide 
Scan 2 
ppAA 
Wide 
Scan 3 
Average 
of ppAA 
Wide 
Scans 
Standard 
Deviation 
(+/-) 
C 1s 282.0 80.48 80.65 80.85 80.66 0.19 
O 1s 529.5 19.52 19.35 19.15 19.34 0.19 
 
The O/C ratio is 0.24. 
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High Resolution XPS Spectrum C1s of ppAA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data of High Resolution XPS Spectrum C1s of ppAA 
 
 
Electrons 
of Atoms 
Detected 
 
Binding 
Energy 
 
FWHM 
Atomic Percentage 
ppAAm C1s 
Scan 1 
ppAAm C1s 
Scan 2 
ppAAm C1s 
Scan 3 
Average of 
ppAAm C1s 
Scans 
Standard 
Deviation  
(+/-) 
C-C 284.9 1.23 70.51 71.64 70.2 70.78 0.76 
C-OR 286.1 1.23 12.50 12.35 11.87 12.24 0.33 
C=O 287.3 1.23 5.544 4.945 7.144 5.88 1.14 
COOR 289.2 1.23 11.44 11.07 10.79 11.10 0.33 
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XPS Wide Scan Spectrum of ppAAm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data of Wide Scans of ppAAm 
 
 
Electrons 
of Atoms 
Detected 
 
Binding 
Energy 
Atomic Percentage 
ppAAm 
Wide Scan 
1 
ppAA 
Wide 
Scan 2 
ppAAm 
Wide Scan 
3 
Average of 
ppAAm 
Wide 
Scans 
Standard 
Deviation 
(+/-) 
C 1s 282.5 77.80 78.88 78.76 78.48 0.59 
N 1s 396.5 19.69 19.29 19.26 19.41 0.24 
O 1s 529.5 2.51 1.83 1.98 2.11 0.36 
 
The O/C ratio is 0.03. 
The N/C ratio is 0.25. 
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High Resolution XPS Spectrum C1s of ppAAm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data of High Resolution XPS Spectrum C1s of ppAAm 
 
 
Electrons 
of Atoms 
Detected 
 
Binding 
Energy 
 
FWHM 
Atomic Percentage 
ppAAm C1s 
Scan 1 
ppAAm C1s 
Scan 2 
ppAAm C1s 
Scan 3 
Average of 
ppAAm C1s 
Scans 
Standard 
Deviation 
(+/-) 
C-C 284.7 1.27 48.13 49.96 46.31 48.13 1.83 
C-N 285.7 1.27 20.03 22.36 22.43 21.61 1.37 
C-OR, 
C=N, NCN 286.5 1.27 28.68 24.76 28.09 27.18 2.11 
C=O, NCO 287.9 1.27 3.16 2.91 3.17 3.08 0.14 
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XPS Wide Scan Spectrum of ppAOH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data of Wide Scans of ppAOH 
 
 
Electrons 
of Atoms 
Detected 
 
Binding 
Energy 
Atomic Percentage 
ppAOH 
Wide 
Scan 1 
ppAOH 
Wide 
Scan 2 
ppAOH 
Wide 
Scan 3 
Average of 
ppAOH 
Wide 
Scans 
Standard 
Deviation 
(+/-) 
C 1s 281.5 88.81 90.04 89.48 89.44 0.62 
N 1s 396.0 2.43 1.97 2.16 2.19 0.23 
O 1s 529.5 8.75 8.00 8.36 8.37 0.38 
 
The O/C ratio is 0.09. 
The N/C ratio is 0.02. 
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High Resolution XPS Spectrum C1s of ppAOH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data of High Resolution XPS Spectrum C1s of ppAOH 
 
 
Electrons 
of Atoms 
Detected 
 
Binding 
Energy 
 
FWHM 
Atomic Percentage 
ppAOH C1s 
Scan 1 
ppAOH C1s 
Scan 2 
ppAOH C1s 
Scan 3 
Average of 
ppAOH C1s 
Scans 
Standard 
Deviation 
(+/-) 
C-C 284.9 1.20 14.32 15.71 17.52 15.85 1.60 
C-C 284.9 1.20 64.09 61.44 59.64 61.72 2.24 
C-N 285.7 1.20 6.44 7.07 7.88 7.13 0.72 
C-OR, 
C=N, NCN 286.5 1.20 8.02 8.80 9.81 8.87 0.90 
C-OR 286.6 1.20 2.33 2.29 0.88 1.83 0.83 
C=O, NCO 287.9 1.20 0.86 0.94 1.05 0.95 0.10 
C=O 287.9 1.20 3.95 3.74 3.22 3.64 0.38 
 
Data in red correspond to components of plasma polymerised allylamine contamination. 
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